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ABSTRACT 
Background: Proper thyroid function is critical for normal fetal growth and 
neurodevelopment, as well as regulation of multiple systems in adults. There is growing 
evidence indicating that exposure to environmental chemicals may disrupt human thyroid 
function. Organophosphate flame retardants (PFRs) and per- and polyfluoroalkyl 
substances (PFASs) are two classes of potential thyroid disrupting chemicals commonly 
used in consumer products. 
Objectives: We characterized exposures to triphenyl phosphate (TPHP), a common PFR, 
and PFASs in two different U.S. populations. We assessed associations between TPHP 
and thyroid hormones in adults, as well as individual and joint associations of prenatal 
PFASs with maternal and neonatal thyroid hormones.  
Methods: Analyses were conducted in two Boston, Massachusetts cohort studies: the 
Flame Retardant Exposure Study (FlaRE) and Project Viva, a longitudinal pre-birth 
cohort. In FlaRE, we used linear mixed effects models to assess covariate-adjusted 
associations between urinary DPHP concentrations and serum thyroid hormone levels in 
repeated samples from male and female adults (n=51). In Project Viva, we used both 
linear regression and weighted quantile sum regression to assess covariate-adjusted 
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individual and joint associations of prenatal plasma PFAS concentrations measured in 
early pregnancy with maternal (n=726) and neonatal (n=465) thyroid hormone levels.  
Results: In FlaRE, higher urinary DPHP was associated with higher total thyroxine (T4) 
levels in female but not male participants. We saw no associations between DPHP and 
free T4, total triiodothyronine, or thyroid stimulating hormone (TSH). In Project Viva, we 
found that higher prenatal exposure to PFASs was associated with lower maternal Free T4 
Index (FT4I) and lower neonatal T4 in male infants, but was not associated with maternal 
T4 or TSH. Combined exposure to multiple PFASs was associated with lower maternal 
FT4I and neonatal T4 levels, but the relative contributions varied by individual PFAS.  
Conclusions: Exposures to both DPHP and PFASs were associated with altered thyroid 
hormone levels in these populations. Observed associations of DPHP and PFASs with 
thyroid hormone levels varied by sex, suggesting potential differences in susceptibility or 
mechanism of action. Associations between PFASs and thyroid hormones also differed 
across chemicals, suggesting potential differences in toxicological mechanism or 
potency. 
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CHAPTER ONE: INTRODUCTION 
Normal thyroid function is critical for proper fetal and child growth and 
neurodevelopment as well as regulating multiple bodily systems throughout adulthood. 
Evidence from animal and human studies has consistently demonstrated that exposure to 
certain environmental chemicals, such as perchlorate, polychlorinated biphenyls (PCBs), 
dioxin, and polybrominated diphenyl ethers (PBDEs), can alter thyroid function (Zoeller 
2010). Because humans are routinely exposed to many different environmental 
chemicals, it is necessary to consider potential effects of exposure to mixtures of thyroid 
disrupting chemicals (Rosofsky et al. 2016; Braun et al. 2016).  
 Organophosphate flame retardants (PFRs) and per- and polyfluoroalkyl 
substances (PFASs) are synthetic chemicals widely used in commercial and consumer 
products, resulting in ubiquitous human exposure in the United States. Toxicological and 
epidemiological studies indicate that these chemicals may alter circulating levels of 
thyroid hormones (Ballesteros et al. 2016; Boas et al. 2010; Meeker et al. 2013a; Zoeller 
2010).  
 
Human thyroid function 
The thyroid system is comprised of two primary hormones: thyroxine (T4) and 
triiodothyronine (T3) (Choksi et al. 2003). T4 is the most abundant hormone and is the 
precursor for T3, the biologically active hormone. Synthesis and release of T4 from the 
thyroid gland is regulated by thyroid stimulating hormone (TSH), which is produced in 
the pituitary gland. TSH and the thyroid hormones form a classic control loop between 
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the pituitary and thyroid glands (Razvi et al. 2010). Reductions in circulating T3 or T4 
promote production and release of TSH by the pituitary gland, which in turn stimulates 
production of T4 in the thyroid gland (Choksi et al. 2003). T3 and T4 are found in both 
protein-bound and free forms in circulating blood; “total” hormone measures represent 
the total amount of circulating hormone, including protein-bound and free form.  
The thyroid system plays an important role in early human development and 
throughout adult life. Healthy thyroid function is crucial for the development and 
continued regulation of the nervous, cardiovascular, immune, and reproductive systems 
in adulthood (Choksi et al. 2003). After diabetes, thyroid disorders are the second most 
prevalent group of conditions of the endocrine system (Razvi et al. 2010). However, even 
subclinical changes in thyroid hormone function have been associated with 
cardiovascular risk factors including increased blood pressure and altered blood lipid 
profiles in adults (Miller et al. 2009; Razvi et al. 2010). Proper thyroid function during 
pregnancy is especially important, as even subclinical changes in circulating thyroid 
hormone levels have been associated with preterm delivery, insufficient fetal growth, and 
neurodevelopmental deficits (de Escobar et al. 2004). Post-birth, neonatal thyroid 
dysfunction has also been associated with impaired cognition and neurodevelopment later 
in childhood (Lyall et al. 2016; Rose et al. 2006; Simic et al. 2009). It is possible that the 
thyroid disrupting effects of many environmental chemicals may mediate the 
neurodevelopmental effects associated with exposures to these chemicals.  
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Organophosphate flame retardants (PFRs) 
 Chemical flame retardants are widely used as additives in commercial and 
consumer products, such as electronics and polyurethane foam. Because these chemicals 
are not chemically bound to the source products, they can be released over time into the 
surrounding environment, resulting in human exposure (Sjödin et al. 2003; Stapleton 
2012; Watkins et al. 2011). PBDEs are brominated flame retardants that were widely 
used in consumer and commercial products starting in the 1970s. PBDEs are both 
environmentally and biologically persistent, with serum half-lives ranging from months 
to years, depending on degree of bromination (Thuresson et al. 2006; Trudel et al. 2011). 
Their persistence and widespread use has led to ubiquitous detection of PBDEs in human 
serum (Linares et al. 2015). Due to concerns over their toxicity and potential health 
effects, PBDEs were voluntarily phased out of use by U.S. manufacturers beginning in 
the early 2000s (EPA 2006; EPA 2010). Since the PBDE phase out, the use of alternative 
and novel flame retardants, including PFRs, has increased (EPA 2008). Like PBDEs, 
PFRs are used as additive chemicals and can escape from source materials into the 
surrounding environment. Consequently, humans may be exposed to PFRs via the indoor 
environment.  
Triphenyl phosphate (TPHP, CAS no. 115-86-6) is an organophosphate ester used 
as both a flame retardant in commercial mixtures, including Firemaster 550®, and a 
plasticizer. It has numerous applications, including polyurethane foam, resins, 
polyvinylchloride (PVC), hydraulic fluids, lacquers, and nail polish (Mendelsohn et al. 
2016; van der Veen and de Boer 2012). Recent studies have detected TPHP at relatively 
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high levels in indoor dust (Stapleton et al. 2009; Stapleton et al. 2012; Dodson et al. 
2012). Consequently, humans may be exposed to TPHP via inhalation, ingestion of 
household dust, or dermal absorption through contact with dust, source materials, or 
direct partitioning from vapor (Pillai et al. 2014). A recent study modeling indoor air 
exposure to TPHP determined that dust ingestion is likely the major route of exposure to 
TPHP, especially for young children (Pillai et al. 2014).  
Analytical methods were recently developed to measure urinary metabolites of 
TPHP, including diphenyl phosphate (DPHP), as biomarkers of TPHP exposure (Cooper 
et al. 2011). Unlike PBDEs, the half-life of TPHP in humans is thought to be relatively 
short, on the order of hours (Hou et al. 2016). However, because of its widespread use 
and presence in indoor environments, an individual’s exposure may be relatively constant 
over time, which could theoretically lead to “pseudo-persistence” and stable internal 
levels in the human body. Previous studies assessing the temporal variability in 
individuals’ urinary DPHP concentrations have generally reported moderate to strong 
reliability in DPHP concentrations over time (Cequier et al. 2015; Hoffman et al. 2014, 
2015b; Meeker et al. 2013b). However, these studies collected samples over relatively 
short time periods (days to months); little is known about variability over longer time 
periods.  
DPHP has been ubiquitously detected in urine samples from U.S. study 
populations (Butt et al. 2014, 2016; Dodson et al. 2014; Hoffman et al. 2014, 2015b; 
Meeker et al. 2013b). Recent evidence suggests that urinary DPHP concentrations have 
increased since the early 2000s, likely due to increased use of TPHP (Hoffman et al. 
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2017). Higher DPHP concentrations have been reported in women compared to men 
(Hoffman et al. 2015b), and reported concentrations in pregnant women have been 
significantly higher compared to concentrations in non-pregnant women (Hoffman et al. 
2017). These differences in DPHP concentrations may be due to differences in exposure 
patterns or physiological differences in metabolism and excretion. DPHP concentrations 
have also been associated with age. Van den Eede et al. (2015) reported an inverse 
association between DPHP concentrations and age in a large Australian study. Other 
studies have reported higher concentrations of DPHP in children compared to adults (Butt 
et al. 2014, 2016; Hoffman et al. 2015a). Higher urinary DPHP concentrations in 
pregnant women and children are of particular concern, as the fetal period and childhood 
may be windows of increased susceptibility to potential health effects of TPHP exposure. 
 
Triphenyl phosphate and thyroid function 
 Despite growing evidence of widespread human exposure to TPHP, relatively 
little is known about its potential human health effects. Because PBDEs have consistently 
been associated with altered levels of circulating thyroid hormones in animals and 
humans (Zhao et al. 2015), there was concern that their replacement chemicals might 
have similar effects. Results of recent toxicology studies have demonstrated potential 
thyroid disrupting effects of TPHP exposure (Kim et al. 2015; Kojima et al. 2013; Liu C 
et al. 2013; Liu X et al. 2016). In vitro and in vivo toxicology studies report that TPHP 
may alter regulation of the hypothalamic pituitary axis (HPT) by altering expression of 
genes, such as the thyrotropin-releasing hormone receptor 2 (trhr2) and thyrotropin-
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releasing hormone genes (Kim et al. 2015; Liu C et al. 2013; Liu X et al. 2016). In vivo, 
TPHP exposure resulted in increased circulating total thyroxine (T4) and triiodothyronine 
(T3) levels in zebrafish (Kim et al. 2015; Liu et al. 2016).  
 Data on associations between TPHP exposure and thyroid function in humans is 
extremely limited. To date only two studies have examined associations between TPHP 
or DPHP and thyroid hormone levels, and both studies were conducted with the same 
study population (Meeker and Stapleton 2010; Meeker et al. 2013a). Both analyses were 
conducted in a small cohort of men from subfertile couples enrolled at a fertility clinic in 
the Boston, Massachusetts (MA) area. Meeker and Stapleton et al. (2010) examined 
associations between concentrations of TPHP in household dust and circulating hormone 
levels. Concentrations of TPHP in dust were suggestively associated with lower free T4 
and higher total T3 levels, but were not associated with thyroid stimulating hormone 
(TSH) levels. In a subsequent exploratory analysis, Meeker et al. (2013a) examined 
associations between urinary DPHP concentrations and the same circulating hormone 
levels as in the their previous analysis. DPHP concentrations were associated with higher 
total T3 levels and were suggestively associated with higher free T4 levels. Neither study 
reported total T4 levels.  
 
Per- and polyfluoroalkyl substances (PFASs) 
 PFASs are a class of persistent organic pollutants characterized by carbon-chains 
surrounded by fluorine atoms. Their carbon fluorine bonds make many PFASs and their 
metabolites resistant to degradation, causing them to be both environmentally and 
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biologically persistent (Olsen et al. 2007). Estimated human half-lives of PFASs vary by 
chain length, but can range from two to eight or more years for longer chain PFASs, such 
as perfluorooctane sulfonic acid (PFOS) and perfluoroctanoic acid (PFOA) (Lau et al. 
2007). Due to their oil- and water-resistant properties, PFASs have been used widely in 
commercial and consumer products such as stain-resistant items, food packaging, 
nonstick coatings, upholstery and fabrics, pesticides, paints, adhesives, and fire-fighting 
foams (Lau et al. 2007; Mariussen 2012; Olsen et al. 2007). Their persistence and 
widespread use has led to ubiquitous human exposure, as demonstrated by detectable 
serum PFAS concentrations in the majority of the U.S. population (Calafat et al. 2007).  
Production of PFASs began in the 1950s and increased dramatically until the 
1990s, when production of the most common PFASs, PFOS and PFOA, peaked (Sagiv et 
al. 2015). Due to health concerns, the major U.S. manufacturer of PFOS voluntarily 
phased-out its production from 2000–2002, as well as production of precursor chemicals 
that can break down to PFOS. Similarly, U.S. manufacturers voluntarily reduced 
production of PFOA and its precursors in 2010 and agreed to end production in 2015 
(Buck et al. 2011; Kato et al. 2011a; D’Eon et al. 2011). These phase-outs are likely the 
cause of the recent reductions in serum concentrations of several PFASs, including 
PFOA, PFOS, and 2-(N-methyl-perfluorooctane sulfonamido) acetate (MeFOSAA), in 
the U.S. population as observed in NHANES (Kato et al. 2011a; D’Eon et al. 2011). 
 Humans are exposed to PFASs primarily through dietary intake of contaminated 
foods and from the indoor environment, via direct contact with PFAS-containing 
products, and via inhalation or ingestion of contaminated dust (Fraser et al. 2012; Lau et 
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al. 2007). However, consumption of contaminated drinking water is a significant route of 
exposure in areas of industrial contamination (Hu et al. 2016). Exposure to PFASs during 
pregnancy is of particular concern, as PFASs are known to cross the placenta and the 
fetus may be particularly susceptible to adverse effects of PFAS exposure. Previous 
research has shown that maternal blood PFAS concentrations are highly correlated with 
concentrations in cord blood (Fromme et al. 2010; Kim et al. 2011). Studies of PFAS 
exposure in pregnant women found lower PFAS concentrations in women with a history 
of prior breastfeeding and higher parity, likely due to maternal-child transfer (Berg et al. 
2014; Brantsaeter et al. 2013; Kato et al. 2014; Sagiv et al. 2015). PFAS concentrations 
have also been associated with demographic and socioeconomic factors such as age, 
education, race, and income, but directions of these associations vary across studies 
(Sagiv et al. 2015).  
Assessing exposure to PFASs during pregnancy using blood PFAS concentrations 
is difficult, as circulating concentrations of PFASs can be influenced by pregnancy-
induced changes in physiology. Unlike many persistent organic pollutants, PFASs do not 
bind to blood lipids and instead bind to albumin (Bartell et al. 2009). During pregnancy, 
plasma volume expansion causes relative albumin concentrations to decrease, which can 
affect measured PFAS concentrations. Additionally, increases in maternal glomerular 
filtration rate (GFR) can lead to increased renal clearance of PFASs from the body 
(Loccisano et al. 2013).  
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PFASs and thyroid function 
 Results from toxicological studies demonstrate that PFASs can disrupt thyroid 
function (Boas et al. 2010; Zoeller 2010). In vivo studies have consistently shown a 
hypothyroid (low T4 and high TSH) or hypothyroxenimia (low T4 and normal TSH) 
pattern in animals following PFAS exposure (Boas et al. 2010; Zoeller et al. 2010). There 
are multiple proposed mechanisms for this effect, including increased hepatic clearance 
of T4, increased conversion of T4 to T3 by type 1 deiodinase (DIO1), reduced 
responsiveness of the HPT axis, and competitive binding to serum thyroid hormone 
binding proteins (Long et al. 2013; Weiss et al. 2009; Yu et al. 2009).  
PFASs have high binding affinities for the thyroid binding proteins, albumin and 
transthyretin, and may competitively bind to these proteins, displacing T4 and T3, which 
could lead to decreases in circulating total T4 and T3 levels as seen in rats (Chang et al. 
2008; D’Eon et al. 2010; Weiss et al. 2009). However, while transthyretin is the primary 
thyroid hormone binding protein in rats, in humans thyroid binding globulin (TBG) is the 
predominant thyroid hormone binding protein (Zantour 2013). A recent study by Ren et 
al. (2016) reported low to no binding affinity of PFASs for TBG, indicating that 
competitive binding may be a less relevant mechanism of PFAS induced alterations in 
thyroid hormone levels in humans. Yu et al. (2009) reported increased expression of 
thyroidal DIO1, involved in T4 to T3 conversion, and hepatic uridine 
diphosphoglucuronosyl transferase (UGT), involved in renal clearance of T4; both could 
result in decreases in circulating T4 levels. Additionally, Ren et al. (2015) reported that 
PFASs could alter thyroid function by directly binding to the human thyroid receptor.  
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While many toxicology studies have only examined effects of the most common 
PFASs, PFOA and PFOS, recent evidence indicates that effects of PFAS exposure on 
thyroid function may vary across individual PFAS chemicals, often by carbon chain 
length and/or functional group (Ren et al. 2015, 2016; Weiss et al. 2009). Thus, different 
PFASs may have different potencies or mechanisms of effect on the thyroid system, and 
coexposure to multiple PFASs could theoretically have additive or interactive effects on 
thyroid function.  
 Effects of PFAS exposure on thyroid function in humans are less well understood. 
While studies have been conducted in occupational and general population settings, this 
section will focus on studies conducted in pregnant women and neonates, as their thyroid 
physiology is somewhat unique and may not be comparable to thyroid function in non-
pregnant adults. Results of studies assessing associations between serum or plasma 
concentrations of PFASs and thyroid hormone levels during pregnancy have been mixed 
(Ballesteros et al. 2016). While the most consistent findings have been positive 
associations between PFAS concentrations [e.g. PFHxS, PFOS, perfluorononanoic acid 
(PFNA)] and TSH levels (Berg et al. 2015; Wang et al. 2013; Wang et al. 2014; Webster 
et al. 2014), Yang et al. (2016) reported inverse correlations between PFAS 
concentrations and TSH in a Chinese cohort. Two studies have reported inverse 
associations between PFASs [e.g. PFOS, PFHxS, PFNA] and free or total T4 levels 
(Wang et al. 2014; Webster et al. 2014), and Berg et al. (2016) reported inverse 
associations of perfluorodecanoic acid (PFDA) and perfluoroundecanoate (PFUnDA) 
with free and total T3 levels. However, it is difficult to compare results across these 
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studies due to substantial heterogeneity in study design, including thyroid hormones 
measured, sample size, sample timing, control for potential confounding factors, and 
geographic location, which can affect population demographics and PFAS exposure 
patterns (Ballesteros et al. 2016).  
One previous study assessed potential effect measure modification of the 
associations of PFASs and maternal thyroid hormone levels by thyroid peroxidase 
antibody (TPOAb) levels (Webster et al. 2014). TPOAb is a marker of thyroid 
autoimmunity, and may be present at elevated levels in individuals with thyroid 
autoimmune diseases such as Hashimoto’s thyroiditis or Graves’ disease (Strieder et al. 
2003). Webster et al. (2014) hypothesized that individuals with elevated levels of TPOAb 
may be more susceptible to the potential thyroid disrupting effects of PFAS exposure. 
Webster et al. found PFASs were inversely associated with free T4 and positively 
associated with TSH levels in women with elevated TPOAb levels, but associations were 
null in women with normal TPOAb levels. However, this was a small study and only 14 
women had elevated TPOAb levels; further research is needed to replicate these findings.  
Compared to studies in pregnant women, fewer studies have assessed effects of 
PFAS on neonatal thyroid function and results have been even more inconsistent. Two 
studies reported inverse associations between prenatal PFAS concentrations, including 
PFOA, PFOS, and PFNA, and cord or total T4 and T3 levels in Taiwanese (Wang et al. 
2014) and South Korean (Kim et al. 2011) cohorts. Conversely, Shah-Kulkarni et al. 
(2016) reported positive cross-sectional associations between cord blood PFASs 
[perfluoro-n-pentanoic acid (PFPeA) and PFDA] and total T4 and T3 in South Korean 
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infants. Kim et al. (2011) reported a positive association between PFOA concentrations 
and TSH levels, while Shah-Kulkarni et al. (2016) reported an inverse association 
between PFNA and TSH in female neonates. Like studies in pregnant women, it is 
difficult to compare results from these neonatal studies due to the heterogeneity in study 
design, especially differences in timing of PFAS measurement (prenatal or cord blood), 
thyroid hormones measured, matrix for hormone measurement (cord blood or post-birth 
heel sticks), control for covariates, stratification by infant sex, and population differences 
in PFAS exposure distributions.  
 
Chemical mixtures  
 Traditionally, epidemiologists have investigated associations between a single 
chemical and a health outcome at a time. Because individuals are not exposed to just one 
chemical at a time, it is necessary to understand the health effects of mixtures of 
exposures. Exposure to an individual chemical may have no effect or a relatively small 
effect on a particular health outcome, but coexposure to even low levels of multiple 
chemicals may potentially yield significant cumulative or interactive effects (Silva et al. 
2002). Unfortunately, traditional epidemiological analysis methods often lack the ability 
to adequately assess the effects of complex mixtures of exposures, especially when the 
exposures are highly correlated with each other, as is often the case with environmental 
chemicals (Braun et al. 2016). Novel statistical methods have been developed to model 
health effects of these complex mixtures, but there is limited information comparing their 
results to more traditional analysis methods using real world data (Taylor et al. 2016). 
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One novel method is weighted quantile sum (WQS) regression, which can be used to 
assess the cumulative effects of a set of correlated exposures on a health outcome and to 
identify the individual exposures within the mixture that contribute to the overall effect 
(Carrico et al. 2014). 
 
Research objectives 
Previous research examining the potential thyroid disrupting effects of TPHP 
exposure in human populations is extremely limited. While toxicology studies suggest 
that TPHP exposure can alter circulating thyroid hormone levels in zebrafish (Kim et al. 
2015; Kojima et al. 2013; Liu C et al. 2013; Liu X et al. 2016), the effects of TPHP 
exposure on thyroid function in humans has only been assessed in one previous study 
population (Meeker and Stapleton et al. 2010; Meeler et al. 2013a). This small study 
population was exclusively made up of male participants with substantially lower urinary 
DPHP concentrations compared to recent studies (Hoffman et al. 2017). Further research 
is needed to explore the effects of TPHP exposure on human thyroid function in larger 
multi-sex study populations.  
Animal studies demonstrate a consistent association between PFAS exposure and 
altered levels of circulating thyroid hormones, but the exact mechanisms behind these 
effects remain unclear (Boas et al. 2010; Zoeller 2010). In humans, studies assessing 
associations between prenatal PFAS exposure and maternal and/or neonatal thyroid 
hormone levels have been less consistent, but have generally reported alterations in 
circulating thyroid hormone levels (Ballesteros et al. 2016). There is substantial 
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heterogeneity in study design, including sample timing (trimester), thyroid hormones 
measures, PFASs measured, and geographic location, which can affect both population 
demographics and PFAS exposure distributions. Most of the previous studies have been 
cross-sectional in nature, have relatively small sample sizes, and few have controlled for 
potential confounding effects of pregnancy physiology, such as plasma volume expansion 
and increased glomerular filtration rate (Ballesteros et al. 2016).  
Associations between PFAS concentrations and thyroid hormone levels in 
humans have varied considerably by specific PFAS chemical and in vivo studies indicate 
that effects of PFASs may vary by chemical chain length and functional group (Ren et al. 
2015 & 2016; Weiss et al. 2009). Few previous epidemiology studies have considered 
effects of coexposure to multiple PFASs, in part due to the high correlations among 
PFASs. Further research is needed in larger studies to examine the effects of prenatal 
exposure to PFASs and maternal and neonatal thyroid function, as well as to examine the 
effects of coexposure to PFAS mixtures.  
 This research aims to address gaps and limitations in the prior literature and to 
further the understanding of thyroid disrupting effects of exposure to the environmental 
chemicals, TPHP and PFASs. To achieve these goals, we conducted research in two 
Boston, Massachusetts (MA) area cohorts, the Flame Retardant Exposure Study (FlaRE) 
and Project Viva. In FlaRE, we characterized urinary DPHP levels in repeat samples over 
a one-year period in male and female office workers, and assessed associations between 
DPHP concentrations and serum thyroid hormone levels. In Project Viva, a prospective 
pre-birth cohort consisting of 2,128 mother-child pairs enrolled during their first prenatal 
  15
visit between 1999 and 2002, we characterized PFAS concentrations in first trimester 
plasma samples and assessed both individual and joint associations of prenatal PFAS 
concentrations with prenatal maternal and neonatal thyroid hormone levels.  
Chapter 2 aimed to characterize and assess the temporal variability in urinary 
DPHP concentrations and to assess associations between urinary DPHP concentrations 
and circulating thyroid hormone levels in 51 healthy U.S. adults enrolled in the FlaRE 
study. We measured urinary DPHP concentrations and serum hormone levels in three 
repeat samples taken over a one-year period. We assessed temporal variability in urinary 
DPHP concentrations and assessed associations of urinary DPHP concentrations with 
serum total and free T4, total T3, and TSH. We assessed potential confounding and effect 
measure modification by covariates, such as coexposures to PBDEs. 
In Chapter 3 we evaluated associations of prenatal plasma PFAS concentrations 
with prenatal maternal and neonatal thyroid hormone levels in a subset of Project Viva 
participants. We measured six PFASs, including PFOA and PFOS, in plasma samples 
collected during the first trimester of pregnancy and examined cross-sectional 
associations with maternal total T4, free T4 Index, and TSH levels, as well as associations 
of prenatal PFASs with neonatal T4 from post-birth heel sticks. We adjusted for potential 
confounding factors, such as pregnancy induced changes in physiology, and examined 
potential effect measure modification by maternal TPOAb status and infant sex.  
The aim of Chapter 4 was to examine the relationships between coexposure to 
multiple PFASs and maternal and neonatal thyroid hormone levels. Building upon our 
analyses in Chapter 3, we used linear regression models to assess associations of prenatal 
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plasma concentrations of multiple PFASs with maternal and neonatal thyroid hormone 
levels. In addition, we used WQS regression to assess the joint effects of PFASs on 
maternal and neonatal thyroid hormone levels and to identify the individual PFASs that 
contributed to these effects. We then compared results from both methods to our results 
from Chapter 3.  
The findings of Chapters 2–4 are summarized in Chapter 5, followed by a 
discussion of the studies’ limitations, public health implications, and directions for future 
research. 
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ABSTRACT 
Triphenyl phosphate (TPHP) is a commonly used organophosphate flame 
retardant and plasticizer with widespread human exposure. Data on health effects of 
TPHP are limited. Recent toxicological studies suggest TPHP may alter thyroid function. 
We used repeated measures to assess the temporal variability in urinary concentrations of 
the TPHP metabolite, diphenyl phosphate (DPHP), and to examine relationships between 
DPHP concentrations and thyroid hormones. We sampled 51 adults at months 1, 6, and 
12 from 2010–2011. Urine samples were analyzed for DPHP. Serum samples were 
analyzed for free and total thyroxine (fT4, TT4), total triiodothyronine (TT3), and thyroid 
stimulating hormone (TSH). We assessed variability in DPHP using intraclass correlation 
coefficients (ICCs) and kappa statistics. We used linear mixed-effects models to examine 
associations between DPHP and thyroid hormones. DPHP was detected in 95% of urine 
samples. Mean DPHP concentrations were 43% higher in women than men. DPHP 
showed high within-subject variability (ICC range, 0.13–0.39; Kappa range, 0.16–0.39). 
High versus low (≥2.65 vs. <2.65 ng/mL) DPHP in all participants was associated with a 
0.43 µg/dL (95% confidence interval: 0.15, 0.72) increase in mean TT4 levels. In sex-
stratified analyses, high versus low DPHP was associated with a 0.91 µg/dL (95% CI: 
0.47, 1.36) increase in mean TT4 in women. The association was attenuated in men 
(βeta= 0.19; 95% CI: -0.15, 0.52). We found no significant associations between DPHP 
and fT4, TT3, or TSH. We found evidence that TPHP exposure may be associated with 
increased TT4 levels, especially in women. 
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INTRODUCTION 
Organophosphate flame retardants are widely used in commercial and consumer 
products (van der Veen and de Boer 2012). Their use has increased over the past decade, 
in part due to the phase out of certain polybrominated diphenyl ethers (PBDEs) such as 
PentaBDE (EPA 2008). Triphenyl phosphate (TPHP, CAS no. 115-86-6) is an 
organophosphate ester used both as a flame retardant and plasticizer, and has been 
applied to polyurethane foam, resins, polyvinylchloride (PVC), hydraulic fluids, lacquers, 
and nail polish (Mendelsohn et al. 2016; van der Veen and de Boer 2012). Like PBDEs, 
TPHP is used as a chemical additive, implying that it is not chemically bound to the 
source material and can escape from products and enter the surrounding environment. 
TPHP has been detected frequently in the indoor environment (Dodson et al. 2014; 
Hoffman et al. 2015b; Meeker et al. 2013b). Humans may be exposed to TPHP through 
inhalation, ingestion of indoor dust, and dermal absorption through contact with dust, 
source materials, or direct partitioning from vapor (Pillai et al. 2014). The half-life of 
TPHP in humans is unknown, but is thought to be on the order of hours to days (Hou et 
al. 2016). However, because of its widespread use and ubiquity in the indoor 
environment, exposures may be relatively constant over time. Constant exposure could 
theoretically create “pseudo-persistence” in the human body, meaning levels of urinary 
metabolites of TPHP would be fairly stable, despite TPHP’s short half-life. 
Methods have been developed to measure diphenyl phosphate (DPHP), a urinary 
metabolite of TPHP. As a biomarker of TPHP exposure, urinary DPHP concentrations 
have been characterized in a growing number of studies, with most U.S. studies reporting 
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ubiquitous detection of DPHP (Butt et al. 2014, 2016; Dodson et al. 2014; Hoffman et al. 
2014, 2015b; Meeker et al. 2013b). While the majority of U.S. studies have been 
conducted in adults, three recent studies measured levels of urinary DPHP in children 
(Butt et al. 2014, 2016; Hoffman et al. 2015a). Four studies have assessed intra-
individual variability of urinary DPHP via repeated measures (Cequier et al. 2015; 
Hoffman et al. 2014, 2015b; Meeker et al. 2013b). However, most of these studies had 
small sample sizes with short sampling periods that may not capture potential long term 
or seasonal variability. 
Despite growing evidence of widespread human exposure, relatively little is 
known about the potential human health effects of TPHP. Preliminary toxicology studies 
suggest that TPHP may disrupt thyroid function (Kim et al. 2015; Kojima et al. 2013; Liu 
C et al. 2013; Liu X et al. 2016). Healthy thyroid function is critical for fetal and child 
growth and development and for maintaining important bodily systems in adults such as 
metabolism, mental health and cognition, and reproduction (Taylor et al. 2013). There is 
increasing evidence that even subclinical changes in adult thyroid function may be 
associated with adverse effects (Taylor et al. 2013). To date only two studies have 
examined associations between TPHP exposure and thyroid function in humans (Meeker 
and Stapleton 2010; Meeker et al. 2013a). These cross-sectional analyses were both 
conducted in a small cohort of men from subfertile couples residing in the Boston, 
Massachusetts (MA) USA area. Additional studies are needed to further explore the 
potential relationship between TPHP exposure and thyroid function in larger and mixed 
sex study populations.  
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TPHP may share exposure sources and routes with PBDEs (Stapleton et al. 
2012b) and were positively correlated in household dust samples in a recent North 
Carolina study (Hoffman et al. 2015b). There is a growing literature linking PBDE 
exposure to thyroid disruption (Czerska et al. 2013; Linares et al. 2015), including 
previous work in the current study cohort (Makey et al. 2015). Therefore, it is important 
to consider potential confounding and/or modification by PBDEs when assessing 
associations between TPHP exposure and thyroid function. 
The current study aims to characterize urinary DPHP concentrations in a 
population of U.S. adults, assess intra-individual variability of repeated DPHP measures, 
and investigate the association between adult DPHP concentrations and thyroid function. 
We measured urinary DPHP and serum thyroid hormones in repeated samples from a 
group of 51 male and female office workers over a one-year period as part of a study 
investigating exposure patterns and health effects of flame retardant chemicals in the 
Boston, MA area. We hypothesized that there would be high intra-individual variability 
in urinary DPHP concentrations over the study period and that DPHP concentrations 
would be associated with altered serum thyroid hormone levels. We explored whether 
factors including PBDEs, urinary iodine, age, or sex might modify associations between 
DPHP and thyroid hormones. Additionally, we characterized urinary DPHP 
concentrations at a single time point in a subset of the study participants’ children.  
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METHODS 
Study participants 
Study subjects were part of the Flame Retardant Exposure Study (FlaRE), which 
has been described previously (Makey et al. 2014). Briefly, a convenience sample of 26 
male and 26 female office workers and a subset of their children (n=14), were recruited 
from the Boston, MA metropolitan area. The fourteen children included some siblings, 
corresponding to nine FlaRE adults. Eligible adult participants were over the age of 18, 
nonsmokers, self-described as healthy, and planning to remain in the Boston area for the 
duration of the study period. Participants were excluded if they had a current or prior 
diagnosis of thyroid disease, male reproductive disease, or were pregnant.  
Serum and urine samples were collected from adults during three sampling rounds 
every six months from January 2010 to May 2011, representing Winter 2010, Summer 
2010, and Winter 2011. Questionnaires were administered at each sample round to collect 
demographic, health, and lifestyle information. During the final sampling round, children 
provided urine samples, and questionnaires were administered to parents to collect 
children’s demographic and behavioral information. Of the 52 adult participants, 41 
completed all three sampling rounds, nine completed two rounds, and two completed one 
round. Samples were excluded from analysis for the following reasons: pregnancy (1 
sample from 1 person), thyroid altering medication use (3 samples from 1 person), and no 
corresponding blood sample (4 samples from 4 people). PBDE data were excluded for 
one sample due to suspected field contamination during collection. The levels of 
hexaBDEs in the sample were ten times those in the individual’s other two samples, 
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while levels of the lower brominated congeners were similar across all three samples, 
suggesting contamination with residential dust containing the octaBDE commercial 
mixture. The final study population consisted of 51 adult participants (135 paired urine 
and serum samples) and 14 children (14 urine samples).  
The Boston University Medical Center Institutional Review Board approved the 
study protocol. All participants provided informed consent and children provided 
informed assent to participate. 
 
Urine samples  
 A single 90 ml spot urine sample was collected from each participant during each 
of the three sampling rounds. Samples were measured for specific gravity (SG) using a 
refractometer and aliquoted before being stored at -20ºC prior to analysis. Urinary DPHP 
was measured at Duke University using previously published methods (Cooper et al. 
2011). Briefly, DPHP was extracted from urine using a mixed-mode anion exchange 
solid-phase extraction cartridge and then analyzed using atmospheric pressure chemical 
ionization liquid chromatography-tandem mass spectrometry (Cooper et al. 2011). 
Deuterated diphenyl phosphate (d10-DPHP) was used as the internal standard for 
quantification. The limit of detection (LOD) was calculated as three times the standard 
deviation of the laboratory blanks and ranged from 0.13–0.21 ng/mL across rounds. 
Sample DPHP values were blank corrected and values below the LOD (adults: n=7, 5%; 
children: n=0, 0%) were replaced with the LOD/√2. All samples were also analyzed for 
urinary iodine concentrations at the Boston University School of Medicine, Section of 
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Endocrinology, Diabetes, and Nutrition using previously published methods (Valentin-
Blasini et al. 2005). The coefficient of variation (CV) for iodine measurements was less 
than 5%. To account for urinary dilution, we SG corrected DPHP and iodine 
concentrations in all analyses except for modeling predictors of DPHP, where we 
included SG as an independent predictor (Boeniger et al. 1993). One sample with an 
extremely low SG (1.0001) was excluded from SG-corrected analyses due to the 
uncertainty surrounding the resulting extreme SG-corrected value. 
 
Blood samples 
 A single 30ml non-fasting blood sample was drawn from each study participant 
during each of the three sampling rounds. Serum samples were stored in amber glass 
vials at -80ºC prior to analysis. Samples from all rounds were analyzed at the Centers for 
Disease Control and Prevention (CDC) for PBDEs using previously published methods 
(Sjödin et al. 2004), and for total serum lipids as previously described (Makey et al. 
2014). PBDE concentrations were standardized to total serum lipid concentrations (ng 
PBDE/g lipid). Samples from all rounds were analyzed for thyroid function at the Boston 
University School of Medicine, Section of Endocrinology, Diabetes, and Nutrition. 
Thyroid peroxidase antibody (TPOAb) was measured using immunometric enzyme 
immunoassay (Orgentec Diagnostika). Thyroid stimulating hormone (TSH), free 
thyroxine (fT4), total thyroxine (TT4), and total triiodothyronine (TT3) were measured 
using enzyme-linked immunosorbent assays (Immuno-Biological Laboratories, Inc). 
Assay reference ranges were: TT4 (women: 4.8–11.6 µg/dL, men: 4.4–10.8 µg/dL), fT4 
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(0.8–2.0 ng/dL), TT3 (0.52–1.85 ng/mL), TSH (0.4–4.2 mIU/L). TPOAb was categorized 
as normal (≤50 IU/mL) or elevated (>50 IU/mL).  
 
Statistical analysis  
Concentration distributions of DPHP, TSH, TT3, and fT4 were skewed and natural 
log (ln)-transformed when used as dependent variables. TT4 was approximately normally 
distributed and was not transformed for analysis. We calculated Spearman correlation 
coefficients between DPHP concentrations and covariates to assess the potential for 
collinearity in our regression models. We calculated descriptive statistics by sampling 
round for DPHP, thyroid function tests, and other analytes.  
We used two methods to assess the temporal variability of the repeated adult 
urinary DPHP measures over the study period. First, we calculated intraclass correlation 
coefficients (ICCs) using continuous DPHP concentrations at the three sampling rounds. 
ICCs represent the ratio of the between-subject variability over the sum of the between- 
and within-subject variability (total variability). ICCs range from zero to one, with ICCs 
close to one indicating good reliability and ICCs close to 0 indicating poor reliability 
(Rosner 2000). ICCs and their 95% confidence intervals (CIs) were calculated with the 
%ICC9 SAS Macro using mixed effects models in SAS PROC MIXED (Hertzmark and 
Spiegelman 2010). In addition to ICCs, we assessed the reliability of an individual’s 
exposure category over the study period using kappa statistics. Kappa statistics quantify 
the amount of agreement between two categorical measurements and range from -1 to 1, 
with 1 indicating perfect agreement, 0 indicating chance agreement, and values <0 
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indicating less than chance agreement (Landis and Koch 1977). We calculated kappa 
statistics between the two winter rounds (rounds 1 and 3) restricted to subjects with urine 
samples from both rounds (n=35). DPHP concentrations were categorized in two ways: 
(1) tertiles of all samples (cut points: T1, 1.44 ng/mL; T2, 2.65 ng/mL), and (2) 
dichotomous categories split at the upper tertile of all samples (“High”, ≥ 2.65 ng/mL; 
“Low”, <2.65 ng/mL). Weighted kappas were calculated for the tertile categories.   
 Due to potential correlations between an individual’s repeated measures we used 
linear mixed effects models with random intercepts to assess predictors of repeated 
DPHP concentrations in adults. Potential predictors included sex, age (years), body mass 
index (BMI) (kg/m2), sample collection time, daily handwashing frequency, and nail 
biting habits. Natural log-transformed uncorrected DPHP levels were modeled as a 
continuous variable. All models were controlled for sample round and SG.  
 Due to the small number of children, we only examined univariate associations of 
each predictor with SG-corrected DPHP concentrations in children using linear 
regression. Potential predictors included demographic and behavioral characteristics. Due 
to lack of variability we did not examine sample collection time in children. We did not 
formally test differences between child and parent mean SG-corrected DPHP levels as we 
had insufficient power to use a hierarchical model clustered by family to account for 
potential correlations between the siblings in our sample.  
 We used linear mixed effects models with random intercepts to assess the 
potential associations between an interquartile range (IQR) increase in SG-corrected 
DPHP concentrations and each serum thyroid hormone in adults, using the data from all 
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three sample rounds. All models were controlled for sample round. We further adjusted 
each model for potential confounding variables including sex, baseline age and BMI 
(kg/m2), and time-varying variables at each round including sample collection time, SG-
corrected iodine (µg/L), and serum PBDEs (ng/g lipid). Potential confounders were 
selected a priori based on directed acyclic graphs and were included in the final models 
using both statistical (changes to beta estimates) and theoretical determinations (Hernan 
et al. 2002). We ran all models adjusting for individual PBDE congeners that had 
previously been associated with thyroid hormones in this population (BDE-47, -99, -100, 
-153) (Makey et al. 2015). Results were similar regardless of which congener was used. 
We included BDE-47 in our final models, as it was most strongly associated with thyroid 
hormone levels.  
We used both continuous and categorical measures of SG-corrected DPHP 
concentrations in our models of thyroid hormone levels. Because the DPHP distribution 
was highly skewed, we categorized SG-corrected DPHP concentrations for each 
individual at each of the three rounds as “High” or “Low” based on the upper tertile 
(High, ≥ 2.65 ng/mL) and the lower two tertiles, (Low, <2.65 ng/mL) of all urine samples 
(all three rounds combined); the lower two tertiles had similar concentration levels and 
were therefore combined. Categorization based on an upper quartile cut point (≥3.28 vs. 
<3.28 ng/mL) yielded similar results (data not shown). We assessed potential effect 
measure modification of the associations between DPHP and thyroid hormones by 
including cross-product terms of DPHP with continuous variables (BDE-47, SG-
corrected iodine, age) and by stratifying by categorical variables [sex, age (cut point at 
   
 
 28
median: ≥36 vs. <36 years)]. All data analysis was performed in SAS version 9.3 (SAS 
Institute Inc., Cary, NC). 
It is unlikely that an individual’s thyroid function and urinary DPHP concentration would 
have been related to an individual not providing or missing a sample. We therefore 
believe our missing data are missing completely at random (MCAR) and should not bias 
the results of our linear mixed effects models, as they are robust to MCAR data 
(Fitzmaurice and Laird 1997; Little and Rubin 2002). 
 
RESULTS 
Study population 
Demographic characteristics of the study population are summarized in Table 2.1. 
The final study population for this analysis consisted of 51 adults and 14 children. Adults 
were evenly split between men and women, mostly white, highly educated, and ranged in 
age from 24 to 66 years, with a median of 36 years. Children were evenly split by sex and 
ranged in age from 3 to 10 years.  
Round-specific summary statistics for adult DPHP, iodine, BDE-47 and thyroid 
hormone measurements are presented in Table 2.2. Adult geometric mean (geometric 
standard deviation, GSD) SG-corrected DPHP concentrations at rounds 1, 2, and 3 were: 
2.99 (2.98), 1.80 (3.30), and 2.11 (2.48) ng/mL, respectively. Spearman correlation 
coefficients (p-values) between SG-corrected DPHP and BDE-47 from rounds 1, 2, and 3 
were 0.29 (0.05), 0.23 (0.12), and -0.17 (0.28), respectively. SG-corrected DPHP was not 
significantly correlated with SG-corrected iodine [round 1: 0.15 (0.30); round 2: 0.10 
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(0.53); round 3: 0.11 (0.49)]. Geometric mean (arithmetic mean for TT4) thyroid hormone 
concentrations were relatively stable across sampling rounds (Table 2.2), and fell largely 
within the normal range. Three women had elevated (>50 IU/mL) TPOAb levels (9 
samples), but their corresponding thyroid hormone measurements were within the normal 
range. The FlaRE population was iodine sufficient, with median urinary iodine 
concentrations >100 µg/L across all three rounds (WHO 2013). Four women (11 
samples) reported taking hormonal oral contraceptives, which increases concentrations of 
thyroxine binding proteins in the blood, and were examined in sensitivity analyses.  
In children, uncorrected and SG-corrected GM (GSD) DPHP concentrations were 
2.11 (1.84) and 2.40 (2.04) ng/mL, respectively. Parents (n=9) had slightly lower GM 
(GSD) uncorrected DPHP levels than children (1.74 (2.78) ng/mL) but had comparable 
GM (GSD) SG-corrected DPHP levels (2.36 (2.30) ng/mL). 
 
Temporal variability of urinary DPHP 
ICCs (95% CI) for DPHP concentrations across all three rounds indicated high 
within-subject variability in DPHP measurement over time [uncorrected: 0.19 (0.06, 
0.45), SG-corrected: 0.13 (0.02, 0.52)]. However, ICCs using only data from the two 
winter rounds (rounds 1 and 3) showed slightly lower variability [uncorrected: 0.39 (0.17, 
0.66), SG-corrected: 0.21 (0.03, 0.69)]. Uncorrected DPHP kappas indicated fair to low 
agreement [tertiles: 0.32 (0.06, 0.58), high/low: 0.20 (-0.13, 0.52)] and SG-corrected 
kappas indicated poor to fair agreement [tertiles: 0.16 (-0.10, 0.41), high/low: 0.39 (0.08, 
0.70)] of individuals’ exposure categories between rounds 1 and 3 (Landis and Koch 
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1977). ICCs for BDE-47, iodine, and thyroid hormone measures were previously reported 
(Makey et al. 2014; Makey et al. 2015). 
 
Predictors of urinary DPHP  
 Results from the multivariable linear mixed model of adult DPHP concentrations 
are presented in Table 2.3. As DPHP concentrations were ln-transformed, we 
exponentiated the beta estimates to represent the adjusted relative mean difference in 
DPHP (ng/mL) compared to the reference group for categorical predictors and the 
relative difference in DPHP (ng/mL) per unit increase in continuous predictors. On 
average, women had 43% higher DPHP concentrations compared to men (relative mean: 
1.43, 95% CI: 0.94, 2.18). DPHP concentrations were higher in samples collected in the 
afternoon (1–5pm) and evening (5–9pm) compared to the morning (7am–1pm). We did 
not find meaningful relationships between DPHP concentrations and participant age, 
BMI, nail biting habits, or daily handwashing frequency.  
 In children, we found no significant associations between SG-corrected DPHP 
concentrations and demographic or behavioral predictors (Table S2.1). 
 
DPHP and thyroid hormones 
Multivariable models of thyroid hormone levels using continuous SG-corrected 
DPHP concentrations were sensitive to two influential observations with extreme DPHP 
values. Model results from sensitivity analyses with and without these observations are 
presented in Table S2.2. Because these models were strongly influenced by individual 
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observations we present our primary model results using categorized SG-corrected DPHP 
concentrations as these models were much more robust.  
Table 2.4 presents the adjusted mean difference (TT4) and relative mean 
difference (fT4, TT3, TSH) in mean hormone levels in the high DPHP group compared to 
the low DPHP group in the full cohort and stratified by sex. All models were adjusted for 
sample round, urine collection time (morning, afternoon, evening), SG-corrected iodine, 
and BDE-47. Models in the full cohort were additionally adjusted for sex. In the full 
cohort, high urinary DPHP was associated with a 0.43 µg/dL (95% CI 0.15, 0.72) 
increase in mean TT4 levels compared to the low DPHP group. The association between 
DPHP level and TT4 differed significantly by sex (sex*DPHP interaction p-value=0.03). 
In women, high urinary DPHP was associated with a 0.91 µg/dL (0.47, 1.36) increase in 
mean TT4 levels compared to low DPHP. In men, mean TT4 levels were only slightly 
higher in the high compared to low DPHP group (0.19 µg/dL; -0.15, 0.52). We saw small 
but less precise positive associations between DPHP and TT3, which did not differ 
significantly between women and men (sex*DPHP interaction p-value=0.84). We did not 
find strong associations between DPHP and fT4 or TSH. Women with high vs. low DPHP 
had lower mean TSH levels, but this estimate was imprecise. SG-corrected iodine, BDE-
47, and age did not modify the associations between DPHP concentrations and thyroid 
hormone levels (interaction p-value ranges: iodine*DPHP, 0.22 to 0.74; BDE-47*DPHP, 
0.34 to 0.89; age*DPHP, 0.13 to 0.94). 
We ran sensitivity analyses to assess the influence of extreme DPHP observations 
(2 samples), women taking oral contraceptives (11 samples), and elevated TPOAb levels 
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(9 samples) on our results. Exclusion of these observations did not meaningfully alter 
results (data not shown); therefore these observations were included in our final models.  
 
DISCUSSION 
We detected DPHP in nearly all urine samples from the FlaRE study population. 
Concentrations were higher in women compared to men, higher in samples collected later 
in the day, and varied significantly within individuals across sampling rounds. We found 
a positive association between SG-corrected DPHP concentrations and TT4 levels among 
women.  
 The geometric mean DPHP concentrations in FlaRE adults fell within the range 
previously reported in studies of U.S. adults (GM ranges: uncorrected, 0.31 to 1.9 ng/mL; 
SG-corrected, 1.2 to 1.9) (Butt et al. 2016; Hoffman et al. 2014, 2015b; Meeker et al. 
2013b). DPHP concentrations in FlaRE adults were considerably higher than in Meeker 
et al. (0.31 ng/mL), the only other study investigating DPHP and thyroid hormone levels 
(Meeker et al. 2013a). This difference may be due to the sampling timing; the Meeker et 
al. population was sampled from 2002 to 2007 and our population was sampled from 
2010 to 2011. Dodson et al. found that levels of TPHP in repeat dust samples were higher 
in 2011 compared to 2006 in CA homes (Dodson et al. 2012). 
 As previously reported, we found higher concentrations of urinary DPHP in 
women compared to men (Hoffman et al. 2015b; Van den Eede et al. 2015). We did not 
collect data on TPHP exposure sources and therefore could not determine if higher DPHP 
in women was due to greater exposure or physiological differences compared to men. As 
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previously reported DPHP concentrations were higher in samples collected in the 
afternoon and evening compared to the morning (Hoffman et al. 2015b; Meeker et al. 
2013a). Because TPHP is thought to have a relatively short half-life, higher DPHP 
concentrations later in the day may indicate that greater TPHP exposure occurs 
throughout the day, potentially outside of the home. More exposure source and activity 
data are needed to investigate these patterns.  
To date only three previous studies have reported DPHP concentrations in 
children in the United States (Butt et al. 2014, 2016; Hoffman et al. 2015a). SG-corrected 
geometric means were higher compared to the FlaRE children (2.9–3.2 vs. 2.4 ng/mL). 
However, these studies sampled younger age groups (<1 to 5 years) and DPHP 
concentrations may be inversely associated with age (Hoffman et al. 2015b; Van den 
Eede et al. 2015). Butt et al. 2014 and 2016 reported higher concentrations of DPHP in 
children compared to their mothers (Butt et al. 2014, 2016). In FlaRE, concentrations in 
children were comparable to those in adults. 
 Although the half-life of TPHP in the human body is unknown, it is thought to be 
metabolized and excreted rapidly from the body, which may cause high intra-individual 
variability in spot urine measures (Aylward et al. 2014; Hou et al. 2016; Muir et al. 
1983). We found markedly lower ICCs over our one-year study period compared to 
previous studies that reported moderate to strong reliability over much shorter time 
periods (ICC range: 0.35 to 0.7; Table S2.4) (Cequier et al. 2015; Hoffman et al. 2014, 
2015b; Meeker et al. 2013b). This indicates that DPHP concentrations may be relatively 
stable in individuals over shorter, but not longer, time periods. Our kappa statistics based 
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on categories of SG-corrected DPHP concentrations showed fair agreement between 
rounds 1 and 3 and ICCs based on data from just those rounds showed moderate 
reliability, indicating that there could be seasonal variability in exposure sources or 
patterns. Cao et al. saw lower concentrations of organophosphate flame retardants in 
office dust in the summer compared to the fall and winter (Cao et al. 2014). We only had 
one summer sampling round and could not formally test the effect of season on DPHP 
levels.  
Subtle changes in circulating thyroid hormones can occur over a relatively short 
period of time due to the short half-lives of T4 (~7 days) and T3 (18 hours) (Anderson et 
al. 2003; Russell et al. 2008). Therefore the moderate to strong reliability previously 
reported for DPHP concentrations over shorter sampling periods may indicate that 
despite the low ICCs for our one-year study period, our spot DPHP measurements may 
be adequate for assessing associations with thyroid hormone levels. Spot samples may 
not be appropriate exposure measures for health outcomes that develop over longer time 
scales. 
 We found a significant positive association between high DPHP concentrations 
and TT4 levels in women and a suggestive positive association with TT3, but did not find 
associations with TSH or fT4. The only other study of urinary DPHP and thyroid 
hormone levels in humans did not report results for TT4, but found a positive association 
between DPHP and TT3 and suggestive positive associations with fT4 and TSH (Meeker 
et al. 2013a). Meeker et al. were unable to explore effect modification by sex because the 
study population was restricted to men (Meeker et al. 2013a). However, we cannot rule 
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out that the lack of association between DPHP and TT4 seen in men in our study could be 
due to limited statistical power rather than lack of a true association. 
In vitro toxicology studies have shown that exposure to TPHP can alter 
expression of genes involved in regulation of the hypothalamic pituitary axis (HPT) (Kim 
et al. 2015; Liu C et al. 2013). In vivo toxicology studies in zebrafish reported increases 
in circulating T4 and T3 following TPHP exposure (Kim et al. 2015; Liu et al. 2016). 
Similarly to our results, Liu et al. reported a significant increase in circulating T4 and T3 
following chronic TPHP exposure in female zebrafish, but did not in males (Liu et al. 
2016). Because we only saw significant associations between DPHP concentrations and 
TT4, an alternative explanation is that the increase in TT4 is due to an increase in protein 
binding of T4 in serum. TPHP increases levels of 17β-estradiol in zebrafish (Liu X et al. 
2013; 2016) and large increases in estrogen can increase serum thyroxine binding 
globulin (TBG) levels (Ain et al. 1987). We did not measure TBG or estrogen levels and 
were unable to investigate this potential mechanism.  
Serum PBDE concentrations, which were previously shown to alter thyroid 
hormone levels in our population (Makey et al. 2015), were positively correlated with 
urinary DPHP at two of the study rounds. Controlling for BDE-47 strengthened the 
associations between urinary DPHP concentrations and TT4 levels in all participants and 
women, but did not meaningfully change the interpretation of our results. Our study is the 
first to assess PBDE coexposures; because both chemicals share similar exposure sources 
and routes and their relationship is still unclear, we believe co-exposures to PBDEs 
should be considered in future studies.  
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 The present study has several limitations. The child sample size was small, which 
limited our ability to assess predictors of DPHP concentrations. Because of the highly 
skewed DPHP distribution and influential points, we categorized DPHP in adults, 
lowering our statistical power. We saw high intra-individual variability in DPHP 
concentrations over the study period, but as previously discussed, spot samples may still 
be sufficient to assess associations with thyroid hormone levels. Recent studies indicate 
that DPHP could also be a metabolite of other aryl-phosphate flame retardants 
(Ballesteros-Gomez et al. 2015; Nishimaki-Mogami et al. 1988). Therefore, it is unclear 
whether TPHP, other DPHP parent compounds, DPHP, or other TPHP metabolites are 
responsible for the observed associations between urinary DPHP and thyroid hormone 
levels. Finally, while we did control for exposure to PBDEs, we cannot exclude the 
possibility of residual confounding due to demographic predictors or co-exposures to 
additional endocrine disrupting compounds. 
 The FlaRE study population was relatively homogenous, limiting the 
generalizability of the study findings to the general population, but potentially reducing 
residual confounding. However, the concentrations of DPHP in the study were similar to 
those reported in most other U.S. study populations. This is only the second study 
assessing associations between urinary DPHP concentrations and thyroid hormone levels 
and the first in a mixed sex cohort. We assessed these associations using repeated 
measures of both exposure and outcome, and controlled for other factors associated with 
thyroid function including iodine status and co-exposure to PBDEs.  
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CONCLUSION 
We found evidence that urinary DPHP concentrations are higher in women and 
may be associated with increased TT4 levels, especially among women. DPHP was not 
strongly associated with TSH or FT4. As TPHP is almost ubiquitously detected in urine 
and this is only the second study to assess these relationships, further studies in larger, 
mixed sex populations are needed to elucidate the relationship between urinary DPHP 
concentrations and thyroid function.  
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Table 2.1 Baseline FlaRE population characteristics 
Characteristic n (%) or mean ± SD 
Adults (n=51)  
Age (years) 40.0 ± 12.7 
Sex 
 
 
Male 26 (51) 
 
Female 25 (49) 
Race/ethnicity 
 
 
White 45 (88) 
 
Other 6 (12) 
Education 
 
 
≥ College graduate 50 (98) 
 
< College graduate 1 (2) 
BMI (kg/m2) 
 
 
< 25 32 (63) 
 
25 – 29.9 17 (33) 
 
≥ 30 2 (4) 
Children (n=14)  
Age (years)  6.6 ± 2.2 
Sex  
 Male 7 (50) 
 Female 7 (50) 
Race/ethnicity  
 White 10 (71) 
 Other 4 (29) 
SD, standard deviation; BMI, body mass index 
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Table 2.2 Summary statistics of analytes by sample round for adults (51 subjects, 135 paired urine and serum samples) 
 Round 1 (n=47)  Round 2 (n=46)  Round 3 (n=42)  
Analytes GM 
(GSD) 
Range  GM (GSD) Range  GM (GSD) Range  
Urinary          
DPHP (ng/ml)          
 Uncorrecteda 1.74 (3.29) 0.12 – 162  0.99 (3.77) 0.14 – 62  1.42 (3.00) 0.15 – 25  
 SG-correctedb 2.99 (2.98) 0.39 – 142  1.80 (3.30) 0.17 – 99  2.11 (2.48)b 0.46 – 25  
Iodide (µg/L)          
 Uncorrecteda 130 (2.19) 27 – 890  102 (2.33) 11 – 382  148 (1.92) 32 – 660  
 SG-corrected b, d 223 (1.62) 78.4 – 815  186 (1.70) 30.3 – 519  240 (1.61) 98.5 – 671  
Specific Gravity c 1.016 
(0.007) 
1.004 – 1.028  1.016 (0.009) 1.003 – 1.035  1.016 (0.007) 1.0001 – 1.027   
Serum          
Hormones          
 TT4 (µg/dL)c 7.30 (1.32) 3.18 – 9.63  7.30 (1.42) 3.9 – 10.2  7.13 (1.24) 4.74 – 9.71  
 fT4 (ng/dL) 1.23 (1.16) 0.93 – 2.09  1.20 (1.19) 0.95 – 2.2  1.19 (1.15) 0.96 – 1.61  
 TT3 (ng/mL) 1.08 (1.17) 0.78 – 1.54  1.06 (1.18) 0.8 – 1.44  1.06 (1.18) 0.84 – 1.54  
 TSH (µIU/mL) 0.71 (1.78) 0.17 – 2.65  0.77 (1.81) 0.16 – 2.27  0.88 (1.98) 0.17 – 4.77  
BDE-47 (ng/g 
lipid)e 
9.52 (2.87) 0.60 – 151  10.26 (2.72) 1.30 – 149  7.93 (2.62) 0.90 – 99  
GM, geometric mean; GSD, geometric standard deviation;  
aUncorrected for urinary dilution 
bSG-corrected for urinary dilution 
cArithmetic mean and standard deviation 
d1 sample excluded during round 3 due to extreme urinary dilution (SG = 1.0001) 
e1 sample excluded during round 3 due to suspected contamination 
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Table 2.3 Adjusteda associations of change in adult urinary DPHP (ln(ng/mL)) 
concentrations by participant characteristics (51 subjects, 135 samples) 
Predictor eβeta (95% CI)b 
Sex  
 Male 1.00 (Ref) 
 Female 1.43 (0.94, 2.18) 
Sample collection time*  
 7:00 am–12:59 pm 1.00 (Ref) 
 1:00–4:59 pm 1.23 (0.75, 2.00) 
 5:00–9:00 pm 2.37 (1.57, 3.57) 
Age (years) 1.00 (0.99, 1.02) 
BMI (kg/m2) 1.02 (0.96, 1.08) 
Handwashing frequency  
(times/day) 
 
 ≤ 6 1.00 (Ref) 
 > 6 1.26 (0.87, 1.84) 
Fingernail biter  
 No 1.00 (Ref) 
 Yes 0.77 (0.49, 1.21) 
ln, natural logarithm; CI, confidence interval; Ref, reference 
aAdjusted for SG, sample round, and covariates in table. 
beβeta represents the relative mean difference in DPHP compared to the reference group 
for categorical predictors and the relative difference in DPHP per unit increase in 
continuous predictors. 
*Global p-value <0.001 
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Table 2.4 Adjusteda associations of change in thyroid hormone levels in high versus low SG-corrected DPHP in all subjects 
and stratified by sex (51 subjects, 133 samplesb) 
   Total T4 (µg/dL)* Free T4 ln(ng/dL) Total T3 ln(ng/mL) TSH ln(mIU/mL) 
Model DPHPd n βeta (95% CI)e eβeta (95% CI)f eβeta (95% CI)f eβeta (95% CI)f 
Allc Low 89 0.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
 High 44 0.43 (0.15, 0.72) 1.01 (0.97, 1.05) 1.03 (0.98, 1.08) 1.05 (0.90, 1.23) 
Women        
 Low  39 0.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
 High  22 0.91 (0.47, 1.36) 1.01 (0.95, 1.07) 1.05 (0.98, 1.13) 0.91 (0.71, 1.68) 
Men        
 Low  50 0.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
 High  22 0.19 (-0.15, 0.52) 1.02 (0.96, 1.08) 1.04 (0.97, 1.11) 1.06 (0.88, 1.27) 
ln, natural logarithm; CI, confidence interval 
aAll models adjusted for sampling round, time of sample collection (morning, afternoon, evening), SG-corrected iodine (µg/L), and 
BDE-47 (ng/g lipid). 
b1 sample excluded due to extreme urinary dilution (SG = 1.0001), 1 sample missing BDE-47 due to potential contamination. 
cModels additionally adjusted for sex. 
d“Low” <2.65 ng/mL, “High” ≥ 2.65 ng/mL 
eβeta represents the absolute mean difference in Total T4 in the high compared to low DPHP group 
feβeta represents the relative mean difference hormone level in the high compared to low DPHP group 
*Sex*DPHP interaction p-value = 0.03 
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Table S2.1 Univariate associations of change in child SG-corrected 
DPHP (ln(ng/mL)) concentrations by participant characteristics (n=14) 
Predictor n eβeta (95% CI)a 
Age (months) 14 1.00 (0.98, 1.01) 
Sex   
 Male 7 1.00 (Ref) 
 Female 7 0.89 (0.38, 2.12) 
Handwashing frequency 
(times per day) 
  
 ≤4 7 1.00 (Ref) 
 >4 7 1.19 (0.50, 2.80) 
Post-meal finger licking 
frequency 
  
 Never/occasionally 6 1.00 (Ref) 
 Often/always 8 0.57 (0.26, 1.25) 
Object-to-mouth frequency   
 Never 7 1.00 (Ref) 
 Occasionally/often 7 0.98 (0.41, 2.31) 
ln, natural logarithm; CI, confidence interval; Ref, reference 
aeβeta represents the relative mean difference in SG-corrected DPHP 
compared to the reference group for categorical predictors and the relative 
difference in SG-corrected DPHP per unit increase in continuous predictors. 
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Table S2.2 Adjusteda associations of change in serum hormone per IQR increase in urinary SG-corrected DPHP 
concentration (51 subjects, 133 samplesb) 
   Total T4 (µg/dL) Free T4 ln(ng/dL) Total T3 ln(ng/mL) TSH ln(mIU/mL) 
Model  n βeta (95% CI)c eβeta (95% CI)d eβeta (95% CI)d eβeta (95% CI)d 
Model Ae 133 -0.0005 (-0.0015, 
0.0006) 
0.997 (0.994, 0.999) 0.999 (0.996, 1.002) 1.009 (1.001, 1.019) 
Model Bf 131 0.03 (-0.01, 0.07) 0.998 (0.993, 1.004) 1.002 (0.996, 1.008) 1.005 (0.984, 1.025) 
IQR, interquartile range; ln, natural logarithm; CI, confidence interval 
aAll models adjusted for sampling round, time of sample collection (morning, afternoon, evening), SG-corrected iodine (µg/L), 
BDE-47 (ng/g lipid), sex. 
b1 sample excluded due to extreme urinary dilution (SG = 1.0001), 1 sample missing BDE-47 due to potential contamination. 
cβeta represents the absolute difference in serum total T4 (µg/dL) per IQR increase in SG-corrected urinary DPHP  
deβeta represents the relative difference in serum hormone level per IQR increase in SG-corrected urinary DPHP 
eModel A: full dataset 
fModel B: excluding DPHP outliers (n=2) 
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Table S2.3 Comparison of urinary DPHP ICCs reported in previous studies arranged by length of sampling 
period 
Study Population 
n 
(# samples) 
Study period 
ICCs 
Uncorrecteda SG-correctedb 
Cequier, 2015 Womend  48 (244) 24 hours 0.37 0.51 
Hoffman, 2015 Men & Women 11 (49) 5 days 0.51 -- 
Hoffman, 2014 
Pregnant 
Women 
8 (24) ~1 week 0.7 0.6 
8 (23) 4–5 months 0.5 0.4 
Meeker, 2013 Men 7 (61) 3 months 0.36 0.35 
This Study Men & Women 51 (135) 1 year 0.19 0.13c 
ICC, intraclass correlation coefficient 
aDPHP concentrations uncorrected for urinary dilution. 
bDPHP concentrations SG-corrected for urinary dilution. 
cn=134, 1 sample excluded due to extreme urinary dilution (SG=1.0001) 
dStudy conducted in Norway; all other studies conducted in the United States 
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ABSTRACT 
Background: Prenatal exposure to some per- and polyfluoroalkyl substances (PFASs) 
may disrupt maternal and neonatal thyroid function, which is critical for normal growth 
and neurodevelopment. 
Objectives: To examine associations of PFAS exposure during early pregnancy with 
maternal prenatal and neonatal thyroid hormone levels. 
Methods: We studied 732 mothers and 480 neonates in Project Viva, a longitudinal pre-
birth cohort in Boston, Massachusetts. We quantified six PFASs including 
perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS), and maternal thyroid 
hormones [thyroxine (T4), Free T4 Index (FT4I), thyroid stimulating hormone (TSH)] in 
plasma samples collected at a median 9.6 weeks gestation and neonatal T4 levels from 
post-partum heel sticks. We estimated associations of PFAS concentrations with thyroid 
hormone levels using covariate-adjusted linear regression models and explored effect 
measure modification by maternal thyroid peroxidase antibody (TPOAb) status and infant 
sex.  
Results: PFAS concentrations were not associated with T4 but were inversely associated 
with maternal FT4I [e.g., -1.75% (95% CI: -3.30, -0.18) per interquartile (IQR) increase 
in PFOA]. PFAS concentrations were inversely associated with TSH levels in TPOAb 
positive women only. Prenatal PFAS concentrations were inversely associated with T4 
levels in male [e.g. PFOS quartile 4 vs. quartile 1: -2.52 µg/dL (95% CI: -4.32, -1.20)] 
but not female neonates [-0.43 µg/dL (95% CI: -1.96, 1.11)].  
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Conclusions: In this study, prenatal exposure to some PFASs during early pregnancy 
was inversely associated with maternal FT4I and neonatal T4 in male infants. These 
results support the hypothesis that prenatal exposure to PFASs influences thyroid 
function in both mothers and infants.   
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INTRODUCTION 
Per- and polyfluoroalkyl substances (PFASs) are synthetic compounds commonly 
used in commercial and consumer products, such as stain-resistant and nonstick coatings, 
food packaging, and firefighting foams (Lindstrom et al. 2011). PFASs can persist in the 
environment and the human body for long periods (2–5 years) (Olsen et al. 2007). The 
persistence and widespread use of some PFASs has resulted in ubiquitous human 
exposure exemplified with detectable PFAS serum concentrations in the majority of the 
U.S. population (Calafat et al. 2007). Humans are exposed primarily through dietary 
intake of contaminated foods and the indoor environment, although exposure through 
contaminated drinking water is also a concern (Hu et al. 2016).  
 Both toxicological and epidemiologic evidence suggests that PFAS exposure may 
alter thyroid function (Ballesteros et al. 2016). Normal thyroid function is critical for 
proper fetal and neonatal growth and neurodevelopment. The fetus is completely 
dependent on maternal thyroid hormones during early pregnancy until 18–20 weeks 
gestation when fetal thyroid hormone production begins (Fisher 1997). Maternal thyroid 
dysfunction, especially during early pregnancy, has been associated with adverse 
pregnancy and developmental outcomes such as impaired fetal growth, preterm delivery, 
and neurodevelopmental deficits, including lower IQ in children (de Escobar et al. 2004). 
Even subtle deficits in maternal thyroid function, such as hypothyroxinemia, can impair 
neurodevelopment in children (Henrichs et al. 2013; Min et al. 2016). Altered neonatal 
thyroid function has also been associated with neurodevelopmental and cognitive deficits 
(Lyall et al. 2016; Rose et al. 2006; Simic et al. 2009). 
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Toxicology studies have consistently demonstrated that PFASs can disrupt 
thyroid function in animals, often leading to a hypothyroidism, characterized by 
decreased total or free thyroxine (T4) and increased thyroid stimulating hormone (TSH), 
or hypothyroxinemia, defined by decreased free T4 (fT4) levels without a concomitant 
increase in TSH (Boas et al. 2012; Zoeller 2010). Studies of the effects of PFAS exposure 
on thyroid function in humans have not been as consistent. Previous studies conducted in 
pregnant women have found associations of higher PFAS serum or plasma concentrations 
with higher TSH levels and/or lower T4 or triiodothyronine (T3) levels, suggesting a 
hypothyroid effect (Berg et al. 2015; Berg et al. 2016; Wang et al. 2013; Wang et al. 
2014), while others have found no associations (Chan et al. 2011) or associations in the 
opposite direction (Yang et al. 2016). Most of the previous studies have had relatively 
small sample sizes and have varied in geographic location, sample timing (trimester of 
pregnancy), thyroid hormones measured, and concentration distributions of PFASs in the 
population. A small study in Canadian pregnant women reported effect measure 
modification of these associations by thyroid peroxidase antibody (TPOAb) status, a 
marker of thyroid autoimmunity (i.e. Graves’ disease, or Hashimoto’s thyroiditis) 
(Webster et al. 2014). The authors hypothesized that the autoimmune damage to the 
thyroid could make individuals more susceptible to thyroid-altering effects of PFASs 
given an already decreased capacity to synthesize thyroid hormones.  
Fewer studies have been conducted in neonates and their results have been even 
less consistent. Studies have reported both positive and negative associations of cord 
blood, heel stick, or prenatal PFAS concentrations with neonatal T4, T3, and/or TSH 
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(Berg et al. 2016; de Cock et al. 2014; Kim et al. 2011; Shah-Kulkarni et al. 2016; Wang 
et al. 2014). Two studies reported sex-specific differences in associations of cord blood 
PFASs with neonatal thyroid hormones (de Cock et al. 2014; Shah-Kulkarni et al. 2016). 
To date studies have varied in timing of PFAS measurement (cross-sectional at birth vs. 
prenatal), hormones measured, matrix analyzed for PFASs and hormones (cord blood vs. 
heel sticks), and geographical location, which can influence population demographics and 
PFAS exposure distributions.  
We examined associations of prenatal PFAS exposure with maternal and neonatal 
thyroid hormone levels in Project Viva, a prospective pre-birth cohort. We also assessed 
potential effect modification by maternal TPOAb status and infant sex. The present study 
is one of the largest to date and the first to quantify PFAS and thyroid hormones during 
early pregnancy (Ballesteros et al. 2016). 
 
METHODS 
Study participants 
Pregnant women were enrolled in Project Viva, a prospective pre-birth cohort in 
the Boston, Massachusetts area, between 1999 and 2002 during their first prenatal visit 
(median 9.6 weeks gestation). Detailed subject recruitment and study protocols were 
previously described (Oken et al. 2015; Sagiv et al. 2015). Of the 2,128 mother-child 
pairs, 1,645 (77%) had maternal PFAS measurements from early pregnancy (median 9.6 
weeks gestation) plasma samples. We measured thyroid hormones in women with 
available blood samples from study visits before 14 weeks gestation. In a previous study 
   
 
 51
in Project Viva, eligible women with complete covariate information on first trimester 
diet and infant cognitive testing provided subsequent consent to us to obtain neonatal T4 
results from the New England Newborn Screening Program (NENSP). Of the 1,645 
participants with PFAS measurements, 768 (47%) had maternal thyroid hormone 
measures, and 501 (30%) had available neonatal T4 results. We excluded 36 women who 
reported prior or current diagnosis of thyroid disease and/or current thyroid medication 
use. The final analytic sample consisted of 732 pregnant women and 480 neonates.  
Institutional Review Boards of all participating institutions approved all study 
protocols and all participating mothers provided written informed consent. The Centers 
for Disease Control and Prevention (CDC) laboratory’s involvement did not constitute 
engagement in human subjects research. 
 
Plasma PFAS concentrations 
Maternal plasma samples were stored as previously described (Sagiv et al. 2015). 
Samples were shipped to the Division of Laboratory Sciences at the CDC (Atlanta, GA) 
where staff quantified six PFAS [perfluorooctanoic acid (PFOA), perfluorooctane 
sulfonate (PFOS), perfluorononanoate (PFNA), perfluorohexane sulfonate (PFHxS), 2-
(N-ethyl-perfluorooctane sulfonamido) acetate (EtFOSAA; also known as Et-PFOSA-
AcOH), 2-(N-methyl-perfluorooctane sulfonamido) acetate (MeFOSAA; also known as 
Me-PFOSA-AcOH)] using previously published methods (Kato et al. 2011b). The limits 
of detection (LOD) were 0.2 ng/mL for PFOS and 0.1 ng/mL for all other PFAS. PFAS 
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were detected in 99–100% of samples; concentrations below the LOD were replaced by 
the LOD/√2 (Hornung et al. 1990).  
 
Maternal and neonatal thyroid assays 
Thyroid stimulating hormone (TSH), total thyroxine (T4), and triiodothyronine 
(T3) resin uptake (T3U) were measured in the same maternal plasma samples used for 
PFAS quantification using the Bayer Advia Centaur assay (Centaur; Bayer Diagnostics, 
Tarrytown, NY). T3U is an indirect measure of thyroid hormone binding protein 
saturation by thyroxine (Dunlap 1990). The Free T4 index (FT4I) was calculated from the 
total T4 and T3U (FT4I = total T4 x T3 Uptake). The FT4I is an estimate of circulating free 
T4 levels, which accounts for changes in T4 levels due to changes in thyroid binding 
protein levels and saturation, such as increases in thyroxine binding globulin (TBG) 
during pregnancy (Lee et al. 2009). Maternal thyroid peroxidase antibody levels 
(TPOAb) were measured using the Nichols Advantage assay (Nichols Institute 
Diagnostics, San Juan Capistrano, CA). The laboratory non-pregnancy reference ranges 
were: total T4, 4.5–10.9 µg/dL; TSH, 0.35–5.50 mIU/L; FT4I, 1.0–4.0; TPOAb 0–2.0 
U/mL. We categorized women as TPOAb positive (>2.0 U/mL) or negative (≤ 2.0 
U/mL), following the laboratory reference range. Eight participants had missing TSH 
data and were excluded from TSH models only. 
We obtained neonatal total T4 levels from NENSP, measured in whole blood on 
filter paper from heel sticks, as previously described (Oken et al. 2009).  
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Covariates 
 We used in-person interviews and questionnaires to collect data on maternal age, 
race/ethnicity, education, smoking habits, marital status, parity, dietary intake, and 
household income. Although we did not have a direct measure of maternal iodine status, 
such as urinary iodine concentration, we had information on maternal use of iodine-
containing supplements and dietary intake of iodine rich foods, including fish, dairy, and 
whole eggs from food frequency questionnaires administered at the time of maternal 
blood sampling. These measures have been used previously to adjust for iodine status in 
the Viva cohort (Oken et al. 2009). We abstracted infant sex and date of birth from 
medical records, and received data on age at heel stick (days) from NENSP. Gestational 
age was estimated from the date of the last menstrual period or second-trimester 
ultrasound if the two estimates differed by >10 days.  
 Both PFAS and thyroid hormone concentrations in plasma are affected by 
physiological changes during pregnancy (Loccisano et al. 2013; Zantour et al. 2013). To 
account for these changes, we assessed markers of pregnancy physiology and 
hemodynamics, including gestational week at blood draw, glomerular filtration rate 
(GFR) and plasma volume expansion (PVE). Higher GFR is associated with greater renal 
clearance of both PFAS and iodine during pregnancy (Loccisano et al. 2013; Sagiv et al. 
2015; Zantour et al. 2013), which could potentially confound the potential association 
between PFAS exposure and thyroid hormones during pregnancy. We calculated GFR 
from plasma creatinine levels using the Cockroft-Gault formula [GFR-CG=(140-age) x 
pre-pregnancy weight (kg) x 1.04/plasma creatinine (µmol/L)] (Morken et al. 2014). We 
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estimated PVE using plasma albumin concentrations and gestational week at blood draw. 
Albumin is both a minor thyroid-binding protein as well as the major binding protein for 
PFAS in blood (Loccisano et al. 2013; Zantour et al. 2013). Plasma creatinine and 
albumin concentrations were quantified in the same samples used for maternal PFAS and 
thyroid hormone analysis at the Children’s Hospital Boston Clinical and Epidemiologic 
Research Laboratory (Boston, MA).   
 
Statistical analyses 
 We examined associations of prenatal plasma PFAS concentrations with maternal 
T4, FT4I, TSH and neonatal T4 levels using multivariable linear regression models. 
Thyroid hormone levels were modeled as continuous outcomes. T3 Uptake measures are 
used to create the FT4I and not as an independent marker of thyroid function. However, 
as a secondary analysis we modeled associations of PFAS concentrations with T3U 
levels, which represent the saturation of thyroid hormone binding proteins in the serum 
and could provide insight into potential binding mechanisms that may explain 
associations with thyroid hormones. Maternal TSH levels and FT4I were skewed, and so 
we natural-log transformed them to meet model assumptions. We report model regression 
coefficients as percent change for ease of interpretation (% change = (exp(beta) - 1) x 
100%). We utilized generalized additive models (GAMs) with continuous PFAS plasma 
concentrations to assess linearity of our models. To reduce the influence of potential 
outliers and examine possible dose-response relationships, we first modeled PFAS 
concentrations as categorical variables using quartiles, and as associations appeared 
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roughly linear across quartiles, we then modeled them as continuous variables. 
Continuous model associations are reported per interquartile range (IQR) increase in 
PFAS concentrations.  
 We controlled for covariates in our models that were potentially associated with 
plasma PFAS concentrations or circulating thyroid hormone levels. Base model 
covariates were selected a priori based on previous literature (Berg et al. 2015; Oken et 
al. 2009; Pearce et al. 2008; Sagiv et al. 2015; Wang et al. 2014) and directed acyclic 
graphs. Maternal thyroid models included: maternal age (years), smoking habits [during 
pregnancy, former (not during pregnancy), never], race/ethnicity (black, white, other), 
parity (0, 1, ≥2), and gestational week at blood draw. Neonatal thyroid models included: 
maternal model covariates and infant sex, gestational age at birth (weeks), route of 
delivery, and age at heel stick (days)]. Next, we assessed potential confounding by 
hemodynamic factors [eGFR (mL/min per 1.73 m2), albumin (g/dL)]. We assessed an 
additional set of potential confounding variables associated with both PFAS 
concentrations and thyroid hormones in bivariate analyses by adding them individually to 
the base adjusted models [maternal education (< college, college, > college), first 
trimester dairy intake (servings per week), and first trimester fish intake (servings per 
week)]. Covariates were included in final models if they changed beta estimates 
appreciably. Final maternal thyroid hormone models were adjusted for maternal age, 
race/ethnicity, smoking habits, parity, gestational week at blood draw, and fish intake. 
Neonatal T4 models were adjusted for maternal age, race/ethnicity, smoking habits, 
parity, gestational week at blood draw, infant sex, age at heel stick, gestational age, and 
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route of delivery. As >99% of participants had complete covariate data, all models were 
run using complete case analysis, excluding those with missing data (maternal n=6, 
neonatal n=15).   
 We assessed effect measure modification by TPOAb status in our maternal 
models using an interaction term and by stratification. In our neonatal model, we assessed 
effect measure modification by infant sex using an interaction term and by stratification.  
 Because maternal thyroid function can affect neonatal thyroid function, maternal 
thyroid hormone levels may be on the causal pathway between prenatal PFAS 
concentrations and neonatal T4 levels (Kuppens et al. 2011). Therefore we chose not to 
control for maternal thyroid hormone levels in our primary analyses and instead 
performed secondary analyses adding each maternal thyroid hormone to our neonatal T4 
models to assess changes in beta estimates.  
 We performed additional sensitivity analyses to assess the robustness of the 
results. To assess the potential influence of incomplete neonatal thyroid development, we 
excluded subjects with gestational ages <37 weeks from the neonatal T4 models. To 
attempt to account for significant variation in neonatal T4 levels due to the postnatal TSH 
surge, we stratified analyses by age at heel stick (<2, ≥2 days).  
 We utilized R version 3.2.4 for GAMs (R Foundation for Statistical Computing, 
Vienna, Austria); all other analyses were conducted in SAS version 9.3 (SAS Institute 
Inc., Cary, NC). 
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RESULTS 
Participant characteristics of the analytic sample and the excluded sample are 
displayed in Table 3.1. Maternal participants averaged 32.5 years of age, were primarily 
white, college graduates, and were evenly split between parous and nulliparous. Mean 
gestational age at time of maternal plasma sample collection was 10.0 weeks, mean 
gestational age at birth was 39.5 weeks, and mean age at heel stick was 2.0 days (range 
0.5–10.1). Maternal characteristics and PFAS concentrations of the subjects in the 
neonatal T4 analysis were similar to those of the full analytic sample (data not shown). 
Participants in the analytic sample were more likely to white and of higher SES (higher 
maternal education, partner education, household income) compared to excluded 
participants (Table 3.1).  
Table 3.2 summarizes the distributions of maternal and neonatal thyroid hormone 
markers and maternal plasma PFAS concentrations. As expected, neonatal T4 levels were 
significantly higher in females compared to males [Mean (SD): females, 18.0 µg/dL 
(4.0); males, 16.9 µg/dL (4.2), p=0.004]. Maternal FT4I was positively correlated with T4 
and negatively correlated with TSH, but maternal T4 and TSH were weakly but not 
significantly correlated with each other. As expected based on previous work in Project 
Viva (Oken et al. 2009), maternal thyroid hormones were not correlated with neonatal T4 
levels (Table S3.1).  
Maternal plasma PFAS distributions are summarized in Table 3.2. PFOS was the 
dominant PFAS (median 24.0 ng/ml), followed by PFOA (5.6 ng/ml). In general, PFASs 
were moderately to strongly correlated with each other (Spearman rs range: 0.19–0.74) 
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(Table S3.1). 
As previously described in this population, T4 and FT4I levels were significantly 
lower and TSH levels were higher in women who were older, white, and TPOAb positive 
(Pearce et al. 2008). FT4I was also lower in women who reported smoking during 
pregnancy. Maternal use of iodine containing supplements was not associated with 
maternal or neonatal thyroid hormones (Oken et al. 2009; Pearce et al. 2008). Gestational 
week at blood draw was weakly correlated with maternal T4 (rs=0.23, p<0.0001) and FT4I 
(rs= -0.19, p<0.0001), but not TSH (rs=-0.06, p=0.10). Plasma albumin levels and eGFR 
were not significantly correlated with thyroid hormone levels. As previously reported, 
PFAS plasma concentrations were lower in women who were older, parous, nonsmokers, 
had higher education attainment, higher eGFR, and lower plasma albumin levels (Sagiv 
et al. 2015).  
 
 Prenatal PFAS plasma concentrations and maternal thyroid hormones 
Adjusted cross-sectional associations of quartiles of first trimester maternal 
PFASs and thyroid hormones are presented in Figure 3.1. We found no meaningful 
associations of maternal PFAS concentrations with T4 or TSH. Concentrations of PFOA 
(Q2–4 vs. Q1), PFHxS (Q4 vs. Q1), and MeFOSAA (Q4 vs. Q1) were consistently 
inversely associated with FT4I levels (effect estimates, Table S3.2). The associations of 
other PFAS with FT4I were consistent in direction of association but estimates were 
weaker.   
Our GAMs showed no evidence of significant departure from linearity overall in 
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the models. Results from adjusted linear PFAS models were similar to the quartile 
models. An IQR increase in PFOA concentrations was associated with a 1.8% (-3.3, -0.2) 
decrease in FT4I. There were no meaningful associations of PFAS concentrations with T4 
or TSH (Table 3.3).  
Maternal T3 Uptake was inversely associated with plasma PFAS concentrations. 
IQR increases in PFOA, PFOS, and MeFOSAA were associated with -2.6% (-4.0, -1.2), -
1.1% (-2.3, 0.07), and -1.2% (-2.2, -0.2) change in T3U levels, respectively.  
 
Effect modification by TPOAb status 
In continuous (IQR) models, cross-sectional associations of maternal PFAS 
concentrations with TSH differed according to TPOAb status (Table 3.4). Associations in 
TPOAb negative women were null. In TPOAb positive women, we saw large but 
imprecise inverse associations of IQR increases in PFOA, PFOS, and PFNA with TSH 
(interaction p-values: PFOA, 0.05; PFOS, 0.04; PFNA, 0.04). Patterns of associations 
were similar in quartile models, but estimates were less precise. TPOAb status did not 
modify associations of PFAS concentrations with T4 or FT4I. 
 
Prenatal plasma PFAS concentrations and neonatal thyroid hormones 
Figure 2 shows the effect estimates and 95% confidence intervals from adjusted 
quartile models in the full sample (a) and stratified by sex (b, c). In all neonates, we 
found a consistent inverse association of PFASs with neonatal T4 levels: PFHxS Q3 vs. 
Q1: -1.0 µg/dL (-2.0, -0.004); Q4 vs. Q1: -1.0 µg/dL (-2.0, -0.01); PFOA Q4 vs. Q1: -
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1.26 µg/dL (-2.3, -0.2); PFOS Q4 vs. Q1: -1.1 µg/dL (-2.1, -0.04). Results from 
continuous PFAS models were similar (Table 3.5). We saw a suggestive inverse 
association between an IQR increase in prenatal PFOA concentrations and neonatal T4 [-
0.4 µg/dL (-0.9, 0.02)]. All other PFAS except PFNA were weakly associated with 
neonatal T4. 
When models were stratified by infant sex, we found inverse associations of 
PFHxS, PFOA, and PFOS with T4 among males, but no associations among females. In 
males, we found consistently lower T4 levels in Q2–4 versus Q1 of PFHxS and PFOS and 
in Q3 and Q4 versus Q1 of PFOA (Table S3.3). A significant interaction by sex 
(sex*PFAS) was present for PFHxS (p = 0.02). Results from continuous models are 
displayed in Table 3.5. In males, IQR increases in PFOA and PFOS were associated with 
-1.02 µg/dL (-1.81, -0.24) and -0.38 µg/dL (-0.91, 0.16) decreases in T4, respectively. 
 
Sensitivity analyses 
When we restricted neonatal models to subjects with heel sticks ≥ 2 days to 
account for the post-delivery TSH surge, adjusted effect estimates did not meaningfully 
differ from results in all neonates (data not shown). Excluding neonates born <37 weeks 
gestation did not appreciably change the results. Additionally, controlling for maternal 
thyroid hormone levels in our neonatal models did not change the effect estimates (data 
not shown). 
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DISCUSSION 
We found inverse associations of PFAS concentrations with FT4I levels in 
maternal plasma collected during early pregnancy, but did not find meaningful 
associations of PFAS concentrations with maternal T4 levels. PFAS concentrations were 
inversely associated with TSH in TPOAb positive women only; associations in TPOAb 
negative women and the full population were null. In neonates, higher prenatal PFAS 
concentrations were associated with lower T4 levels in males, but not females.  
Our main results are generally consistent with reports from animal studies, which 
tend to report decreases in total T4 levels following exposure to PFASs, usually PFOA or 
PFOS (Boas et al. 2012; Zoeller 2010). There are multiple potential mechanisms for the 
thyroid disrupting effects of PFASs, including competitive binding to thyroid hormone 
binding proteins (Weiss et al. 2009), increased hepatic clearance of T4 and increased 
conversion of T4 to T3 by type 1 deiodinase (Yu et al. 2009), and reduced responsiveness 
of the hypothalamic-pituitary-thyroid axis (Long et al. 2013).  
Most PFASs have a high binding affinity for albumin (D'Eon et al. 2010) and 
transthyretin (Chang et al. 2008; Weiss et al. 2009), but have low to no binding affinity 
for thyroxine-binding globulin (Ren et al. 2016). While transthyretin is the major thyroid 
binding protein in rats, thyroxine-binding globulin is the major thyroid binding protein in 
humans (Zantour et al. 2013). Our study does not support competitive binding of PFAS to 
thyroid binding proteins as the main mechanism behind the observed inverse associations 
with FT4I. We found that higher concentrations of PFASs were associated with decreased 
saturation of plasma binding proteins. In our study, PFAS concentrations were inversely 
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associated with T3U. If PFASs were competitively binding to thyroid binding proteins, 
we would expect that greater PFAS concentrations would be associated with higher T3U 
due to increased saturation of plasma binding proteins. It is more likely that the inverse 
associations between PFASs and FT4I in our study resulted from increased metabolism of 
T4 and/or conversion of T4 to T3 by type 1 deiodinase. Yu et al. (2009) found that 
thyroidal type 1 deiodinase and hepatic uridine diphosphoglucuronosyl transferase, both 
involved in conversion of T4 to T3, were significantly increased following PFOS 
exposure in rats (Yu et al. 2009). Increased conversion of T4 to T3 could result in lower 
free T4 levels, but normal or elevated T3 levels, which would result in stable or decreased 
TSH levels. Unfortunately, we did not measure T3 levels in our study.  
It is also important to note that many toxicology studies have only looked at 
effects of one or two PFASs, usually PFOS or PFOA, and while PFASs share similar 
structural features, they may differ in mechanisms of effect and potencies. Additionally, 
most animal studies use doses that are significantly higher than those experienced by 
general human populations and interspecies differences may make it difficult to compare 
effects of PFASs on thyroid function in rats to effects in humans.  
Inverse associations of maternal PFASs with FT4I seen in our cohort were also 
reported in a Taiwanese cohort (free T4) (Wang et al. 2014) and in TPOAb positive 
women in a Canadian cohort (Webster et al. 2014). We found no associations between 
TSH and PFASs in the full Viva cohort, but in TPOAb positive women, higher PFAS 
concentrations were associated with lower TSH. While the majority of previous studies 
reported positive associations between PFASs and TSH (Berg et al. 2015; Wang et al. 
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2013; Wang et al. 2014; Webster et al. 2014), Yang et al. (2016) found an inverse 
association between PFAS concentrations and TSH in a Chinese cohort. Lack of 
consistency across studies could be due to the considerable variation in study design 
including differences in timing of sample collection (trimester), hormones measured, 
population demographics, and distributions of PFAS concentrations.   
Only one previous study assessed effect modification by TPOAb status in 
pregnant women (Webster et al. 2014). Contrary to our findings, they found interquartile 
range increases in PFNA, PFOA, and PFOS concentrations were associated with 
increased TSH levels in TPOAb positive women. However, that study was substantially 
smaller than ours (n=14 TPOAb positive women vs. n=98 in our study), and results from 
both studies could be affected by limited sample sizes. Webster et al. collected blood 
samples later in pregnancy (15 and 18 weeks gestation vs. median 9.6 weeks in our 
study) and median PFAS concentrations were lower in Webster et al. (2014) compared to 
Project Viva (e.g. PFOS: 4.8 vs. 24.0 ng/mL in our study), which could affect 
comparability between studies. It remains unclear exactly how TPOAb status may modify 
the association between PFAS exposure and thyroid hormone levels. Further research is 
needed to understand these relationships. 
Few studies have examined associations of PFAS exposure with neonatal thyroid 
hormones. In our study we found an inverse association of prenatal PFAS concentrations 
with neonatal T4 levels, consistent with results from a Taiwanese study of 116 neonates 
(Wang et al. 2014) and a South Korean study of 43 neonates (Kim et al. 2011). Two 
studies reported sex specific effects that were inconsistent with our results of inverse 
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associations of PFASs with T4 in male but not female neonates; neonatal T4 levels were 
positively associated with PFASs in female but not male neonates in Dutch (PFOA) (de 
Cock et al. 2014) and South Korean infants (PFHxS and PFNA) (Shah-Kulkarni et al. 
2016). The reason for this sex difference is unclear. In our cohort, male neonates had 
significantly lower T4 levels compared to females, which may make males more 
susceptible to alterations in thyroid function (Chan et al. 2011; Herbstman et al. 2008; 
Kuppens et al. 2011). The discrepancies in results among studies may be due to 
differences in study design, population demographics, or PFAS concentrations 
distributions. While we measured PFASs prenatally, de Cock et al. (2014) and Shah-
Kulkarni et al. (2016) measured PFASs at birth. Shah-Kulkarni et al. (2016) measured 
neonatal hormones in cord blood, while blood from neonatal heel sticks a few days after 
birth was used to measure neonatal hormones in de Cock et al. (2014) and in our study.  
 Reductions in FT4I levels alone could potentially impact fetal growth and 
neurodevelopment. We measured maternal hormones during early pregnancy, when the 
fetus is completely dependent on the mother for thyroid hormones. Maternal 
hypothyroxinemia has been consistently associated with cognitive and psychomotor 
deficits in the offspring (de Escobar 2001; de Escobar et al. 2004; Henrichs et al. 2013). 
Offspring are particularly susceptible to these effects when hypothyroxinemia occurs 
during early pregnancy (de Escobar et al. 2004; Henrichs et al. 2013). The effects of low 
neonatal T4 levels are less well understood, but altered neonatal thyroid function has been 
associated with reductions in neurocognitive test, IQ, and attention scores (Lyall et al. 
2016; Rose et al. 2006; Simic et al. 2009).   
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The present study has several strengths and limitations. To our knowledge this is 
the second largest study of PFAS concentrations and thyroid hormones in pregnant 
women, the largest study in neonates, and the first conducted in a U.S. cohort. Because of 
our large sample size we were able to investigate effect measure modification by 
maternal TPOAb status in a much larger sample of women than previously reported and 
also by sex in neonatal models. In our maternal analysis PFASs and thyroid hormones 
were measured cross-sectionally, limiting our ability to establish temporality. However, 
this is potentially offset as several PFASs, including PFOA, PFOS, and PFHxS, have 
relatively long half-lives in plasma, measured in years; concentrations in a single blood 
sample are likely representative of an individual’s exposure over relatively long time 
periods. Unlike previous studies, we collected maternal blood in first trimester of 
pregnancy, when physiological changes such as plasma volume expansion and increased 
GFR are less likely to affect both PFAS and thyroid hormone measurements compared to 
later pregnancy. Unlike most previous studies, we were able to assess potential 
confounding effects by pregnancy induced physiological factors such as plasma volume 
expansion and increased GFR, by controlling for plasma albumin levels and eGFR in 
addition to controlling for gestational week at blood draw. However, in our study, 
albumin and eGFR did not confound the observed associations.  
We estimated fT4 using the FT4I, not by equilibrium dialysis, considered the gold 
standard for fT4 measurement during pregnancy. However, unlike fT4 immunoassay 
methods, which are sensitive to alterations in binding proteins and prone to bias during 
pregnancy, the FT4I accounts for alterations in binding proteins and has been shown to 
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accurately represent fT4 levels during pregnancy (Lee et al. 2009). Additionally, we did 
not measure T3, which may have allowed us to better understand the relationship between 
PFASs and FT4I and TSH. Unfortunately, we did not have data on maternal iodine status, 
an important determinant of maternal and neonatal thyroid function. However, we did 
have information on use of iodine containing supplements and dietary intake of iodine 
rich foods. 
We measured neonatal T4 in whole blood from heel sticks rather than cord blood, 
which may be less influenced by stress during birth (Tehrani et al. 2003). However, our 
neonatal T4 measurements came from the New England Newborn Screening Program 
with a median time of heel stick of 44 hours post-birth and it is possible that the post-
birth TSH surge could have caused substantial measurement error in our data. When we 
restricted our analyses to neonates with heel sticks performed ≥ 2 days, results were not 
meaningfully different than in all neonates, suggesting that outcome misclassification 
from the post-birth TSH surge did not affect our results.  
The Project Viva population is less racially diverse and of higher socioeconomic 
status than the general population, limiting the generalizability of our results. However, 
the homogeneity of the cohort may help reduce residual confounding and concentrations 
of PFASs in the Viva population were comparable to those in the U.S. general population 
during the corresponding time period (Sagiv et al. 2015). We cannot rule out potential 
residual confounding from uncontrolled factors such as coexposures to other endocrine 
disrupting chemicals; however, previous studies have found low correlations between 
PFASs and other chemical classes (Robinson et al. 2015; Rosofsky et al. 2016). 
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CONCLUSION 
Women with higher plasma concentrations of PFOA, PFHxS, and MeFOSAA had 
significantly lower levels of FT4I during early pregnancy compared to women with the 
lowest concentrations. In TPOAb positive women, increases in PFOA, PFOS, and PFNA 
concentrations were associated with lower TSH levels. We saw no associations of PFASs 
concentrations with T4 levels in women. In neonates, higher prenatal concentrations of 
PFHxS, PFOA, and PFOS were associated with lower T4 levels, especially among males. 
Changes in maternal FT4I associated with PFASs were relatively small, and may not be 
clinically relevant to the individual pregnant women or their offspring. However, even 
small deficits in maternal free T4, especially during early pregnancy, can have significant 
adverse effects on fetal growth and neurodevelopment. 
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Table 3.1 Maternal and neonatal characteristics in the analytic study population and excluded 
population 
    Study participants   Excluded participants 
  n Mean ± SD or n (%)   n Mean ± SD or n (%) 
Maternal/family characteristics 732   1396  
Age at enrollment (years) 732 32.5 ± 4.7 
 
1396 31.5 ± 5.4 
Dietary intake 
     
 
fish (daily servings) 728 0.2 ± 0.2 
 
1049 0.2 ± 0.3 
 
whole eggs (weekly servings) 728 0.3 ± 0.3 
 
1049 0.3 ± 0.3 
 
total dairy (weekly servings) 728 2.7 ± 1.5  
 
1049 2.6 ± 1.5 
Gestational weeks at blood draw  724 10.0 ± 2.2 
 
944 10.2 ± 2.4 
eGFR (mL/min/1.73 m2) 721 115.3 ± 61.8 
 
909 105.4 ± 36.1 
Albumin (g/dL) 676 5.8 ± 1.3 
 
915 6.2 ± 1.1 
Race/ethnicity 732 
  
1372 
 
 
black 
 
74 (10) 
  
274 (20) 
 
white 
 
561 (77) 
  
838 (61) 
 
other 
 
97 (13) 
  
260 (19) 
Parity 732 
  
1396 
 
 
0 
 
365 (50) 
  
652 (47) 
 
1 
 
255 (35) 
  
506 (36) 
 
≥2 
 
112 (15) 
  
238 (17) 
Smoking History 730 
  
1377 
 
 
former 
 
143 (20) 
  
255 (18) 
 
during pregnancy 
 
77 (10) 
  
189 (14) 
 
never 
 
510 (70) 
  
933 (68) 
Education 732 
  
1372 
 
 
<college 
 
188 (26) 
  
556 (41) 
 
college 
 
286 (39) 
  
457 (33) 
 
>college 
 
258 (36) 
  
359 (26) 
Iodine containing supplements 728 
  
1348 
 
 
no 
 
678 (93) 
  
1306 (97) 
 
yes 
 
50 (7) 
  
42 (3) 
TPOAb status 732 
  
45 
 
 
negative (≤ 2 U/mL) 
 
631 (86) 
  
16 (36) 
 
positive (> 2 U/mL) 
 
101 (14) 
  
29 (64) 
Partner education 690 
  
1214 
 
 
< college 
 
193 (28) 
  
482 (40) 
 
college 
 
267 (39) 
  
404 (33) 
 
> college 
 
230 (33) 
  
328 (27) 
Household income 696 
  
1178 
 
 
<$40K 
 
71 (10) 
  
222 (19) 
 
$40K–70K 
 
171 (25) 
  
264 (22) 
 
>$70K 
 
454 (65) 
  
692 (59) 
Child characteristics 480   1648  
Age at heel stick (days) 467 2.0 ± 0.7 
 
30 1.9 ± 0.6 
Gestational age (weeks) 480 39.5 ± 1.9 
 
1648 39.4 ± 2.0 
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Table 3.1 Continued 
    Study participants   Excluded participants 
  n Mean ± SD or n (%)   n Mean ± SD or n (%) 
Sex 480   1648  
 
male 
 
244 (51) 
  
852 (52) 
 
female 
 
236 (49) 
  
796 (48) 
Cesarean 480 
  
1648 
 
 
no 
 
371 (77) 
  
1229 (76) 
  yes   108 (23)     390 (24) 
SD, standard deviation; eGFR, estimated glomerular filtration rate; TPOAb, thyroid peroxidase 
antibodies 
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Table 3.2 Maternal plasma PFAS and maternal and neonatal hormone distributions in the analytic study population 
 
Maternal Analysis (n=732) 
 
Neonatal Analysis (n=480)  
  
Median 
(25th – 75th percentile) 
Range 
 
Median 
(25th – 75th percentile) 
Range  
Prenatal plasma PFAS 
(ng/mL)       
 
PFOS 24.0 (17.6 – 32.6) 2.8 – 115 
 
23.5 (17.3 – 31.1) 4.6 – 115 
 
 PFOA 5.6 (3.9 – 7.7) 0.3 – 36.7  5.5 (4.0 – 7.6) 0.9 – 20.1  
 PFHxS 2.4 (1.6 – 3.8) <LOD – 43.2  2.3 (1.6 – 3.8) <LOD – 43.2  
 
PFNA 0.6 (0.5 – 0.8) <LOD – 6.0 
 
0.6 (0.5 – 0.9) <LOD – 6 
 
 
EtFOSAA 1.1 (0.7 – 1.7) <LOD – 33.6 
 
1.0 (0.7 – 1.7) <LOD – 33.6 
 
 
MeFOSAA 1.8 (1.2 – 2.9) 0.1 – 29.7 
 
1.8 (1.2 – 2.8) 0.1 – 29.7 
 
Thyroid Hormones       
 
Total T4 (µg/dL) 9.9 (8.7 – 11.2) 3.9 – 24.4  
17.3 (14.7 – 20.1) 3.7 – 35.7 
 
 
Free T4 Index 2.1 (1.9 – 2.3) 1.3 – 6.0  
NA NA 
 
 
TSH (mIU/mL)a 1.2 (0.7 – 1.9) <0.01 – 21.4 
 
NA NA 
 
PFAS, per- and polyfluoroalkyl substances; PFOS, perfluorooctane sulfonate; PFOA, perfluorooctanoate; PFHxS, 
perfluorohexane sulfonate; PFNA, perfluorononanoate; EtFOSAA, 2-(N-ethyl-perfluorooctane sulfonamide) acetate; 
MeFOSAA, 2-(N-methyl-perfluorooctane sulfonamide) acetate; T4, thyroxine; TSH, thyroid stimulating hormone.  
The limits of detection (LOD) were 0.2 ng/mL for PFOS and 0.1 ng/mL for all other PFASs. 
an=724, 8 participants missing TSH values 
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Table 3.3 Adjusteda change in maternal thyroid hormone levels per IQR increase in 
plasma PFAS concentrations (n=726) 
 Total T4 (µg/dL)  Free T4 Index  TSHb (mIU/mL) 
PFAS Beta (95% CI)  % change (95% CI)  % change (95% CI) 
PFOS 0.01 (-0.14, 0.16)  -1.04 (-2.36, 0.29)  0.84 (-7.32, 9.73) 
PFOA 0.09 (-0.09, 0.27)  -1.75 (-3.30, -0.18)  0.30 (-9.30, 10.9) 
PFHxS -0.05 (-0.14, 0.04)  -0.58 (-1.36, 0.21)  2.76 (-2.25, 8.03) 
PFNA -0.05 (-0.16, 0.05)  -0.65 (-1.61, 0.33)  -0.55 (-6.50, 5.77) 
EtFOSAA -0.01 (-0.09, 0.06)  0.09 (-0.60, 0.78)  -0.08 (-4.32, 4.36) 
MeFOSAA 0.03 (-0.10, 0.15)  -0.85 (-1.95, 0.27)  1.05 (-5.84, 8.44) 
aAdjusted for maternal age, race/ethnicity, smoking status, fish intake, parity, and 
gestational week at blood draw 
bn=718, 8 participants missing TSH values 
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Table 3.4 Adjusteda change in maternal TSH (mIU/mL) per IQR increase in 
plasma PFAS concentrations stratified by TPOAb status  
 TPOAb Negative (n=620)b  TPOAb Positive (n=98)b 
 % change (95% CI)  % change (95% CI) 
PFOS 2.88 (-5.97, 12.6)  -16.7 (-30.2, -0.67) 
PFOA 1.51 (-8.71, 12.9)  -21.9 (-37.6, -2.38) 
PFHxS 3.02 (-2.53, 8.88)  -6.18 (-14.2, 2.56) 
PFNA 0.38 (-5.86, 7.03)  -15.2 (-28.6, 0.81) 
EtFOSAA 0.28 (-4.12, 4.88)  -5.82 (-16.8, 6.53) 
MeFOSAA 0.67 (-6.59, 8.49)  -5.59 (-19.2, 10.3) 
TPOAb, thyroid peroxidase antibody 
aAdjusted for maternal age, race/ethnicity, smoking status, fish intake, parity, 
and gestational week at blood draw 
b TPOAb negative, ≤ 2 IU/mL; TPOAb positive, > 2 IU/mL) 
PFAS*TPOAb interaction p-values: PFOS, 0.04; PFOA, 0.05; PFHxS, 0.25; 
PFNA, 0.04; EtFOSAA, 0.43; MeFOSAA, 0.86 
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Table 3.5 Adjusteda change in neonatal T4 (µg/dL) per IQR increase in prenatal plasma 
PFAS concentrations in all neonates and stratified by sex  
 
All (n=465)b 
 
Male (n=236)   Female (n=229) 
  Beta (95% CI)   Beta (95% CI)   Beta (95% CI) 
PFOS -0.09 (-0.44, 0.26) 
 
-0.38 (-0.91, 0.16) 
 
-0.14 (-0.66, 0.37) 
PFOA -0.45 (-0.92, 0.02) 
 
-1.02 (-1.81, -0.24) 
 
-0.32 (-0.97, 0.33) 
PFHxS -0.15 (-0.38, 0.09) 
 
-0.49 (-0.87, -0.11) 
 
0.09 (-0.23, 0.41) 
PFNA 0.09 (-0.25, 0.44) 
 
-0.30 (-0.89, 0.30) 
 
0.21 (-0.26, 0.68) 
EtFOSAA -0.08 (-0.27, 0.10) 
 
0.09 (-0.44, 0.61) 
 
-0.15 (-0.37, 0.06) 
MeFOSAA -0.13 (-0.43, 0.17)   -0.07 (-0.45, 0.31)   -0.32 (-0.94, 0.30) 
aAdjusted for maternal age, race/ethnicity, smoking status, parity, gestational week at 
maternal blood draw, cesarean delivery, gestational age, and age at heel stick 
bAdditionally adjusted for infant sex 
PFAS*sex interaction p-values: PFOS, 0.18; PFOA, 0.44; PFHxS, 0.01; PFNA, 0.19; 
EtFOSAA, 0.22; MeFOSAA, 0.89 
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Table S3.1 Spearman correlation coefficients among prenatal plasma PFAS concentrations (ng/mL) and maternal (n=732) 
and neonatal (n=480) thyroid hormones  
        Maternal  Neonatal 
 
PFOS PFOA PFHxS PFNA EtFOSAA MeFOSAA T4  FT4I TSH   T4  
PFOS 1 0.74** 0.52** 0.63** 0.49** 0.39** 0.02 -0.01 -0.03  -0.06 
PFOA  
1 0.52** 0.55** 0.38** 0.36** 0.01 -0.07 0.01  -0.04 
PFHxS   
1 0.43** 0.19** 0.26** -0.05 -0.05 0.02  -0.06 
PFNA    
1 0.19** 0.24** -0.04 0.01 0.04  -0.01 
EtFOSAA     
1 0.41** -0.06 -0.05 -0.03  0.03 
MeFOSAA      
1 0.003 -0.06   -0.08*  -0.04 
Maternal           
 
 
 T4 (µg/dL)       
1 0.47** -0.24  0.01 
 FT4I         
1 -0.34**   0.005 
 TSH (mIU/mL)         
1   0.006 
Neonatal T4 
(µg/dL)          
 1 
**p<0.0001, *p<0.05 
TSH n=724 
          
 
 
 
 
 
 
   
 
 75
Table S3.2 Adjusteda change in maternal thyroid hormone levels per quartile (Q2–4 vs. 
Q1) of plasma PFAS concentrations (n=726) 
  
Total T4 (µg/dL) 
 
Free T4 Index 
 
TSH (mIU/mL)b 
PFAS 
 
Betac (95% CI) 
 
% changed (95% CI) 
 
% changed (95% CI) 
PFOA Q1 0.00 (Ref)  
0.00 (Ref) 
 
0.00 (Ref) 
 
Q2 -0.13 (-0.52, 0.26)  
-4.57 (-7.83, -1.20) 
 
15.3 (-7.68, 43.9) 
 
Q3 0.005 (-0.39, 0.40)  
-2.76 (-6.12, 0.73) 
 
10.1 (-12.0, 37.8) 
 
Q4 0.009 (-0.40, 0.42)  
-6.30 (-9.67, -2.81) 
 
8.32 (-14.2, 36.8) 
       
PFOS Q1 0.00 (Ref)  
0.00 (Ref) 
 
0.00 (Ref) 
 
Q2 0.28 (-0.10, 0.67)  
-0.60 (-3.97, 2.88) 
 
-6.58 (-24.9, 16.1) 
 
Q3 0.14 (-0.25, 0.53)  
-1.56 (-4.95, 1.94) 
 
-5.43 (-24.2, 18.0) 
 
Q4 0.31 (-0.08, 0.71)  
-1.55 (-4.96, 1.97) 
 
-4.85 (-23.8, 18.8) 
       
PFNA Q1 0.00 (Ref)  
0.00 (Ref) 
 
0.00 (Ref) 
 
Q2 0.02 (-0.39, 0.43)  
-1.97 (-5.50, 1.69) 
 
22.5 (-2.86, 54.4) 
 
Q3 0.08 (-0.29, 0.45)  
-0.49 (-3.76, 2.89) 
 
12.1 (-9.16, 38.3) 
 
Q4 -0.09 (-0.46, 0.28)  
-1.18 (-4.39, 2.14) 
 
5.50 (-14.4, 30.0) 
       
PFHxS Q1 0.00 (Ref)  
0.00 (Ref) 
 
0.00 (Ref) 
 
Q2 -0.24 (-0.61, 0.14)  
-0.32 (-3.62, 3.09) 
 
7.22 (-13.5, 32.8) 
 
Q3 0.10 (-0.29, 0.49)  
-0.27 (-3.68, 3.27) 
 
-9.09 (-27.1, 13.3) 
 
Q4 -0.34 (-0.73, 0.04)  
-4.24 (-7.47, -0.89) 
 
3.08 (-17.1, 28.1) 
       
EtFOSAA Q1 0.00 (Ref)  
0.00 (Ref) 
 
0.00 (Ref) 
 
Q2 -0.10 (-0.48, 0.28)  
-0.26 (-3.59, 3.19) 
 
-4.47 (-23.0, 18.5) 
 
Q3 -0.26 (-0.65, 0.14)  
-2.47 (-5.85, 1.04) 
 
13.6 (-9.18, 42.1) 
 
Q4 -0.22 (-0.61, 0.16)  
-2.76 (-6.06, 0.65) 
 
4.93 (-15.6, 30.5) 
       
MeFOSAA Q1 0.00 (Ref)  
0.00 (Ref) 
 
0.00 (Ref) 
 
Q2 0.05 (-0.33, 0.43)  
-1.82 (-5.11, 1.58) 
 
13.0 (-8.99, 40.2) 
 
Q3 0.07 (-0.31, 0.46)  
-3.03 (-6.33, 0.38) 
 
-3.13 (-22.2, 20.7) 
 
Q4 0.009 (-0.38, 0.40)  
-3.93 (-7.24, -0.50) 
 
-1.30 (-20.9, 23.2) 
aAdjusted for maternal age, race/ethnicity, smoking status, fish intake, parity, and gestational 
week at blood draw 
bn=718, 8 participants missing TSH values 
cBeta estimate represents the absolute change in T4 level per quartile (Q2–4 vs. Q1) of PFAS 
concentration 
d% change estimate represents the % change in hormone level per quartile (Q2–4 vs. Q1) of 
PFAS concentration 
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Table S3.3 Adjusteda change in neonatal T4 (µg/dL) per quartile (Q2–4 vs. Q1) of 
plasma PFAS concentrations in all neonates and stratified by sex 
  Allb (n=465)  Female (n=234)  Male (n=243) 
PFAS  Beta (95% CI)  Beta (95% CI)  Beta (95% CI) 
PFOS Q1 0.00 (ref)  0.00 (ref)  0.00 (ref) 
 Q2 
-0.64 (-1.65, 0.36)  -0.29 (-1.78, 1.21)  -2.01 (-3.54, -0.48) 
 
Q3 -0.3 (-1.33, 0.73)  0.14 (-1.37, 1.65)  -1.89 (-3.51, -0.28) 
 
Q4 -1.07 (-2.10, -0.04)  -0.43 (-1.96, 1.11)  -2.76 (-4.32, -1.20) 
  
  
 
  
 
  
PFOA Q1 0.00 (ref)  0.00 (ref)  0.00 (ref) 
 Q2 
-0.46 (-1.49, 0.56)  -0.21 (-1.72, 1.30)  -0.84 (-2.45, 0.77) 
 
Q3 -0.40 (-1.44, 0.64)  0.49 (-1.10, 2.07)  -1.69 (-3.28, -0.11) 
 
Q4 -1.26 (-2.34, -0.18)  -0.99 (-2.55, 0.58)  -2.52 (-4.22, -0.83) 
       
PFHxS Q1 0.00 (ref)  0.00 (ref)  0.00 (ref) 
 Q2 -0.76 (-1.78, 0.26)  -0.43 (-1.94, 1.08)  -1.76 (-3.30, -0.21) 
 
Q3 -0.99 (-1.97, -0.004)  -0.27 (-1.76, 1.21)  -1.84 (-3.34, -0.34) 
 
Q4 -1.02 (-2.02, -0.01)  0.20 (-1.30, 1.69)  -2.51 (-4.02, -1.00) 
       
PFNA Q1 0.00 (ref)  0.00 (ref)  0.00 (ref) 
 Q2 -0.33 (-1.40, 0.75)  0.001 (-1.68, 1.68)  -1.02 (-2.65, 0.60) 
 
Q3 -0.61 (-1.52, 0.31)  -0.23 (-1.56, 1.10)  -1.17 (-2.59, 0.26) 
 
Q4 -0.44 (-1.47, 0.60)  0.21 (-1.43, 1.85)  -1.26 (-2.77, 0.25) 
    
 
  
 
  
EtFOSAA Q1 0.00 (ref)  0.00 (ref)  0.00 (ref) 
 
Q2 -0.19 (-1.23, 0.86)  0.28 (-1.27, 1.82)  -0.76 (-2.33, 0.81) 
 
Q3 0.29 (-0.68, 1.26)  0.73 (-0.72, 2.19)  -0.13 (-1.62, 1.36) 
 
Q4 0.36 (-0.65, 1.38)  0.40 (-1.09, 1.88)  0.04 (-1.58, 1.67) 
    
 
  
 
  
MeFOSAA Q1 0.00 (ref)  0.00 (ref)  0.00 (ref) 
 Q2 
0.23 (-0.80, 1.27)  0.40 (-1.13, 1.94)  -0.20 (-1.76, 1.36) 
 
Q3 -0.14 (-1.12, 0.84)  0.86 (-0.58, 2.31)  -1.44 (-2.97, 0.08) 
 
Q4 -0.6 (-1.62, 0.41)  -0.64 (-2.13, 0.86)  -0.53 (-2.09, 1.03) 
aAll models adjusted for maternal age, race/ethnicity, smoking status, parity, gestational week at 
maternal blood draw, child sex, cesarean delivery, gestational age, and age at heel stick 
bModels additionally adjusted for infant sex 
PFAS*sex interaction p-value: PFOS, 0.07; PFOA, 0.16; PFHxS, 0.02; PFNA, 0.57; EtFOSAA, 
0.82; MeFOSAA, 0.33 
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Figure 3.1 Effect estimates and 95% confidence intervals for associations of quartiles of 
plasma PFASs with (a) T4 (n=726), (b) Free T4 Index (n=726), and (c) TSH (n=718) in 
early pregnancy maternal plasma samples. 
 
Effect estimates represent change in (a) T4 (µg/dL) or percent change in (b) Free T4 Index and (c) 
TSH for PFAS quartiles 2–4 versus quartile 1. Models were adjusted for maternal age, 
race/ethnicity, smoking status, fish intake, parity, and gestational week at blood draw. The 
horizontal line represents null association. 
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Figure 3.2 Effect estimates and 95% confidence intervals for associations of quartiles of 
prenatal plasma PFAS with neonatal T4 in (a) all neonates (n=465), (b) males (n=236), 
and (c) females (n=229). 
  
 
Models were adjusted for maternal age, race/ethnicity, smoking status, parity, gestational week at 
maternal blood draw, cesarean delivery, gestational age, and age at heel stick. (A) Models 
additionally adjusted for infant sex. The horizontal line represents null association. PFAS*sex 
interaction p-values: PFOS, 0.07; PFOA, 0.16; PFHxS, 0.02; PFNA, 0.57; EtFOSAA, 0.82; 
MeFOSAA, 0.33. 
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ABSTRACT 
Background: Proper maternal and neonatal thyroid function is critical for normal growth 
and neurodevelopment. Prenatal exposure to individual per- and polyfluoroalkyl 
substances (PFASs) has been shown to alter circulating thyroid hormone levels, but few 
studies have investigated effects of combined exposure to multiple PFASs. 
Objectives: To assess associations between coexposure to multiple PFASs during early 
pregnancy with maternal prenatal and neonatal thyroid hormone levels using weighted 
quantile sum (WQS) regression.  
Methods: The study population was a subset of the Boston, Massachusetts area 
longitudinal pre-birth cohort, Project Viva, consisting of 726 mothers and 465 neonates. 
We measured maternal thyroxine (T4), Free T4 Index (FT4I), TSH and six PFASs 
[perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), perfluorononanoate 
(PFNA), perfluorohexane sulfonate (PFHxS), 2-(N-ethyl-perfluorooctane sulfonamido) 
acetate (EtFOSAA), and 2-(N-methyl-perfluorooctane sulfonamido) acetate 
(MeFOSAA)] in maternal plasma samples collected during early pregnancy and neonatal 
T4 in post-partum heel sticks. We assessed associations between coexposure to all six 
PFASs and thyroid hormone levels using linear regression models and WQS regression, 
adjusting for relevant covariates.  
Results: Individual PFASs were moderately to highly correlated (Spearman rs range: 
0.19 to 0.74; median: 0.41; p<0.0001). In linear regression models containing all six 
PFASs, an interquartile range increase in PFOA was suggestively associated with 
decreased maternal FT4I and was significantly associated with decreased T4 in male 
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neonates. In WQS regression analyses, the weighted sum of PFAS concentrations was 
significantly associated with decreased maternal FT4I [% change: -3.05 (95% confidence 
interval (CI): -5.16, -1.00)]. Based on their weights, PFHxS, PFOA, PFOS, and 
MeFOSAA were the largest contributors to that association. In neonates, the weighted 
sum of PFAS concentrations was significantly associated with decreased T4 levels in 
males [beta: -1.04 µg/dL (95% CI: -1.62, -0.46)] but not females [beta: -0.22 µg/dL (95% 
CI: -0.33, 0.81)]. PFHxS, PFOA, PFOS, and MeFOSAA had the largest weights, 
indicating they were the biggest contributors to the association among neonates.  
Conclusions: These results support the hypothesis that there are combined effects of 
prenatal exposure to PFASs on maternal and neonatal thyroid hormone levels, and that 
individual PFASs may contribute differently to these effects.  
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INTRODUCTION 
Proper maternal and neonatal thyroid function is critical for normal growth and 
neurodevelopment. During early pregnancy the fetus is completely dependent on 
maternal thyroid hormones until fetal thyroid hormone production increases around 18–
20 weeks gestation (Fisher 1997). After birth, normal thyroid function is necessary to 
regulate continued growth and neurodevelopment during childhood, as well as 
metabolism and other major organ systems throughout adulthood (Miller et al. 2009). 
Alterations in maternal thyroid function are associated with adverse fetal outcomes 
including preterm delivery, insufficient fetal growth, and neurodevelopmental deficits (de 
Escobar et al. 2004). Additionally, neonatal thyroid dysfunction has been associated with 
impaired cognition and neurodevelopment (Lyall et al. 2016; Rose et al. 2006; Simic et 
al. 2009).  
Recent epidemiological studies suggest that prenatal exposure to per- and 
polyfluoroalkyl substances (PFASs) may disrupt normal maternal and neonatal thyroid 
function (Ballesteros et al. 2016). PFASs are a group of fluorinated synthetic compounds 
commonly used in consumer and industrial products such as stain-resistant and non-stick 
coatings, firefighting foams, food packaging, upholstery, and carpeting (Lindstrom et al. 
2011). Due to their strong fluorocarbon chains, PFASs are environmentally and 
biologically persistent (Olsen et al. 2007). Exposure to PFAS contaminated drinking 
water is an emerging issue of concern in areas of previous industrial contamination. 
However, the general population is primarily exposed to PFASs through diet and the 
indoor environment (Fraser et al. 2012; Gebbink et al. 2015; Hu et al. 2016). Widespread 
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exposure to PFASs has resulted in ubiquitous detection of PFASs in human serum in the 
U.S. population (Calafat et al. 2007).  
 Toxicology studies have demonstrated that PFASs can disrupt thyroid function in 
animals often leading to a hypothyroid-like effect, with reduced levels of circulating total 
thyroxine (T4) or free T4, with or without an increase in TSH (Boas et al. 2012; Zoeller 
2010). Previous epidemiologic studies assessing associations between PFAS exposure 
and thyroid hormone levels in pregnant women and neonates have been inconsistent, but 
have generally found associations between higher PFAS serum or plasma concentrations 
and lower free or total T4 levels and/or increased TSH levels (Ballesteros et al. 2016). In 
Chapter 3, we reported that prenatal plasma concentrations of some PFASs levels were 
inversely associated with maternal Free T4 Index (FT4I) levels and neonatal T4 levels, 
especially in male neonates in the Project Viva study population.  
Most previous epidemiologic studies have assessed associations of each 
individual PFAS and thyroid hormones, without evaluating possible combined effects of 
multiple PFASs. Only two studies performed sensitivity analyses including multiple 
PFASs in the same regression model (Chan et al. 2011; Shah-Kulkarni et al. 2016), and 
one study assessed associations between multiple chemicals, including seven PFASs, and 
maternal thyroid hormone levels using principle components analysis and hierarchical 
clustering methods (Berg et al. 2016). To our knowledge no studies have investigated 
joint effects of exposure to multiple PFASs on neonatal thyroid hormone levels.  
Recently there has been increased recognition of the need to investigate health 
effects of exposure to multiple exposures, or mixtures. It is well understood that 
   
 
 84
individuals are exposed to many different environmental chemicals at once (Rosofsky et 
al. 2016; CDC 2017). However, traditionally epidemiologists have assessed associations 
between environmental exposures and health outcomes by modeling individual exposure-
outcome relationships. This practice has multiple potential problems including lack of 
control for confounding by correlated coexposures, increased likelihood of false-positive 
results due to multiple comparisons, and lack of an estimate of the joint effect of 
exposure to the chemical mixture (Braun et al. 2016). If the number of exposures of 
interest is relatively small, all exposures may be included in the same model to control for 
mutual confounding. However, there may be insufficient statistical power to detect subtle 
associations between the outcome and multiple exposures if the sample size is not 
sufficiently large, interpretation of the individual and joint effects of the exposures can be 
difficult, and issues of multicollinearity can occur if the exposures are highly correlated 
(Braun et al. 2016). Multicollinearity due to high correlations between exposures can 
make it difficult to separate the individual effects of correlated variables and can cause 
effect estimates to be unstable due to model coefficients with large variances (Rothman 
2008).  
There has been a recent increase in the development of novel statistical methods 
to address the issue of assessing associations between mixtures of exposures and health 
outcomes (Taylor et al. 2016). One such method is weighted quantile sum (WQS) 
regression. WQS regression can be used with multiple moderately to highly correlated 
exposures to assess associations between a health outcome and the joint effect of multiple 
exposures with the same direction of effect, while identifying which individual exposures 
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are contributing to the overall association using estimated empirical weights (Carrico et 
al. 2014).  
 The goal of this analysis was to use WQS regression to assess associations 
between maternal and neonatal thyroid hormone levels and combined prenatal exposure 
to six PFASs, to identify which individual PFASs were the largest contributors to these 
associations, and to compare results to those from traditional linear regression methods. 
This analysis was conducted as an extension of our previous work in Chapter 3, using 
data from a subset of the Project Viva population, a prospective pre-birth cohort in the 
Boston, Massachusetts area. To our knowledge, this study is the first to use WQS 
regression to assess associations between PFASs and thyroid hormone levels. 
 
METHODS 
Study participants 
As described in Chapter 3, the study population consisted of a subset of pregnant 
women and their neonates enrolled in the Project Viva prospective pre-birth cohort study 
between 1999 and 2002. Women were enrolled at their first prenatal visit (median 9.6 
weeks gestation) where plasma samples and detailed participant information including 
medical history, demographics, and dietary intake were collected. Of the 2,128 eligible 
participants, 768 had both plasma PFAS measures and maternal thyroid hormone 
measurements, and 501 had both plasma PFAS measures and neonatal T4 data. The 
neonatal T4 data were obtained from the New England Newborn Screening Program 
(NENSP). Thirty-six women currently using thyroid medication and/or with a prior or 
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current diagnosis of thyroid disease and 6 women and 15 neonates with missing covariate 
information were excluded from the present analysis. The final study population for this 
analysis included 726 pregnant women and 465 neonates.  
 The Centers for Disease Control and Prevention (CDC) laboratory’s involvement 
did not constitute engagement in human subjects research. Study protocols were 
approved by the Institutional Review Boards of all other participating institutions and all 
participating women provided written informed consent.  
 
PFAS quantification 
  As described by Sagiv et al. (2015), maternal plasma samples were collected in 
early pregnancy and stored prior to analysis. Samples were analyzed at the Division of 
Laboratory Sciences at the CDC (Atlanta, GA) for six PFASs [perfluorooctanoic acid 
(PFOA), perfluorooctane sulfonate (PFOS), perfluorononanoate (PFNA), 
perfluorohexane sulfonate (PFHxS), 2-(N-ethyl-perfluorooctane sulfonamido) acetate 
(EtFOSAA; also known as Et-PFOSA-AcOH), 2-(N-methyl-perfluorooctane 
sulfonamido) acetate (MeFOSAA; also known as Me-PFOSA-AcOH)] as previously 
described (Kato et al. 2011b; Sagiv et al. 2015). PFASs were detected in 99–100% of 
plasma samples with the following limits of detection (LOD): PFOS, 0.2 ng/mL; all other 
PFASs, 0.1 ng/mL. Concentrations of PFASs below the limit of detection were replaced 
by the value of the LOD/√2.  
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Thyroid hormone quantification 
 Levels of thyroid stimulating hormones (TSH), total thyroxine (T4), and 
triiodothyronine (T3) resin uptake (T3U) were quantified in the same maternal samples as 
described above, using the Bayer Advia Centaur assay (Centaur; Bayer Diagnostics, 
Tarrytown, NY) at Boston University School of Medicine. The free T4 index (FT4I) was 
calculated using total T4 and T3U levels, and was used as an estimate of circulating free 
T4 levels, accounting for potential changes in thyroid binding protein levels such as 
increased levels of thyroid binding globulin (TBG) during pregnancy (Lee et al. 2009). 
The following non-pregnancy reference ranges were provided by the laboratory: total T4, 
4.5–10.9 µg/dL; TSH, 0.35–5.50 mIU/L; FT4I, 1.0–4.0. TSH levels for 7 women were 
below the method limit of detection (0.01 mIU/L) and were replaced by values of 0.01/√2 
for this analysis. An additional 8 women had missing TSH data and were excluded from 
all TSH models.  
 As previously described by Oken et al. (2009), subsequent maternal consent was 
obtained to access neonatal T4 measurements from the NENSP, which measured neonatal 
T4 in whole blood collected on filter paper from post-partum heel sticks.  
 
Statistical Analysis  
We calculated summary statistics and distributions of PFASs and thyroid 
hormone levels in mothers and neonates. We used Spearman rank correlation coefficients 
to calculate the degree of correlation among PFASs and with maternal and neonatal 
thyroid hormones. Building upon our previous analysis of individual PFAS-hormone 
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associations using multivariable linear regression models (single-PFAS models) in 
Chapter 3, we examined associations between all six PFASs and individual thyroid 
hormones using both traditional regression methods and a novel statistical method, WQS 
regression (Carrico et al. 2014). All models were adjusted for potential confounding 
covariates, described and identified in our previous analysis (maternal thyroid model 
covariates: maternal age, race/ethnicity, smoking habits, parity, gestational week at blood 
draw, and fish intake; neonatal thyroid model covariates: maternal age, race/ethnicity, 
smoking habits, parity, gestational week at blood draw, child sex, age at heel stick, 
gestational age, and cesarean delivery). In all analyses, thyroid hormone levels were 
modeled as continuous outcomes and TSH and FT4I were ln-transformed. 
 
Multi-PFAS linear regression 
Using a traditional regression approach, we built upon our single-PFAS models 
from Chapter 3 and created covariate-adjusted multivariable linear regression models for 
each thyroid hormone including all PFASs in each model (multi-PFAS models). PFASs 
were modeled as continuous variables and associations are reported per interquartile 
range (IQR) increase in PFAS concentration. TSH and FT4I were natural-log transformed 
to meet model assumptions; associations from TSH and FT4I regression models are 
reported as percent change for ease of interpretation [% change = (exp(beta)-1)*100%]. 
We calculated variance inflation factors for each PFAS in the model to quantify the 
degree of multicollinearity.  
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WQS regression  
Using WQS regression, we estimated associations between each thyroid hormone 
and the combined exposure to all 6 PFASs. WQS regression has been described in detail 
in Carrico et al. (2014). Briefly, WQS regression simultaneously estimates empirical 
weights for each exposure based on their association with the outcome of interest. These 
weights are then applied to exposure quantiles and combined to create a single exposure 
index (weighted quantile sum index), which is then used as a single exposure variable in 
regression models to assess associations between the outcome of interest and the six 
PFASs. The effect estimate for the WQS index can be interpreted as an estimate of the 
mixture effect on the outcome, while the individual exposure weights can be used to 
identify the relative contributions of each chemical to this effect. WQS regression 
assumes that there is a linear association with the outcome across the quantiles and that 
no interactions exist between the exposures. The specific steps of the WQS regression 
method are described in more detail below.  
First, concentrations of each PFAS were categorized into quantiles (qi), where 
q1=0, q2=1, q3=2, and q4=3. We chose to use quartiles based on our analysis in Chapter 3. 
WQS regression requires the user to specify the direction of association in either the 
positive or negative direction. Based on our previous analysis, we constrained maternal 
T4 and FT4I and neonatal T4 models to be negative, and TSH models to be positive. Next, 
the dataset was randomly split into a training dataset and a test dataset. If the dataset is 
too small to split and/or the results are not robust to splitting, the method can be 
performed using the single original dataset, but the type I error is increased. Therefore, 
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we randomly split the maternal dataset into equally sized datasets, but used the full 
dataset for all of our neonatal T4 analyses due to the smaller sample size that was less 
robust to splitting. We used a bootstrap step in the training dataset (full dataset for 
neonatal analyses) to estimate the weights of each PFAS (wi) based on their association 
with the outcome. The weighted mean of the 1,000 bootstrap weights was then calculated 
for each PFAS. The total weighted index of the total exposure to PFASs, or the weighted 
quantile sum (WQS), was then created by summing the weighted quartiles of all PFASs 
(∑wi*qi).  
The validation dataset was then used to test the significance of the effect of the 
WQS index based on independent data, using the following model: 
 
g(µ) = β0 +  β1 + (∑i=1 wi*qi) + z’     [Equation 1] 
 
Where β0 is the intercept, ′ is a vector of covariates,  is a vector of corresponding 
regression coefficients, and g represents the link function, the identify function in our 
models, linking the predictor variables to the thyroid hormone mean, µ. ∑i=1 wi*qi 
represents the weighted index of the 6 PFASs, where wi is the weight for each individual 
PFAS categorized into quartiles, qi. Weights for all PFASs are constrained by 0 ≤ wi ≤ 1, 
and must sum to 1, ∑i=1 wi = 1. β1 is the regression coefficient for the weighted index and 
can be interpreted as the combined effect of exposure to the weighted index of PFASs on 
the outcome. If the slope of β1 is positive, there is an overall positive association with the 
outcome, if the slope is negative there is an overall negative association with the 
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outcome. Following Carrico et al. (2014), if the effect of the WQS is statistically 
significant, the user can further interpret the individual weights from the WQS. Weights 
for each PFAS can be interpreted as the relative contribution of that PFAS to the 
association with the outcome. Components that do not contribute to the association 
between the WQS index and the outcome have small weights often approaching zero.   
  
Sensitivity analyses 
 In our sensitivity analyses, we ran WQS regression models constraining the 
direction of association between PFASs and the thyroid hormones in the opposite 
direction compared to our main analysis above (i.e. neonatal T4 and maternal T4 and FT4I 
constrained positive, maternal TSH constrained negative) to assess whether there may be 
a joint effect of PFASs on the thyroid hormones in the opposite direction than what we 
hypothesized or observed in our single-PFAS analysis in Chapter 3. 
 
RESULTS 
Participant characteristics 
The characteristics of our study population have been previously described in 
detail in Chapter 3 (Table 3.1). Briefly, maternal participants were primarily white 
(77%), nonsmoking (70%), college graduates (74%) with a mean age of 32.5 years. 
Median time of maternal blood draw was 9.6 weeks gestation. Neonates were evenly split 
between males (51%) and females (49%) and had a mean gestational age of 39.5 weeks. 
Neonatal heel sticks were performed at a mean of 2.0 days post-partum.  
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PFAS concentrations and thyroid hormone levels 
Table 4.1 summarizes the distributions of prenatal plasma PFAS concentrations, 
as well as maternal and neonatal thyroid hormone levels. Neonatal T4 levels were 
significantly higher in female compared to male neonates. Prenatal plasma PFAS 
concentrations were comparable in maternal and neonatal subsets (Table 3.2). PFOS 
concentrations were highest (median 23.9 ng/mL), followed by PFOA (5.6 ng/mL) and 
PFHxS (2.4 ng/mL). Spearman correlation coefficients among prenatal plasma PFAS 
concentrations and maternal and neonatal thyroid hormone levels are summarized in 
Table 4.2. PFASs were moderately to strongly correlated with each other (Spearman rs 
range: 0.19–0.74; median: 0.41; p<0.0001). Neonatal T4 was not correlated with maternal 
thyroid hormone levels. Maternal FT4I was positively correlated with T4 and negatively 
correlated with TSH.   
 
Multi-PFAS linear regression models 
 Table 4.3 displays the model results for covariate-adjusted associations between 
each maternal thyroid hormone and IQR increases in plasma PFAS concentrations, in 
both single- and multi-PFAS models. Compared to the single-PFAS models, effect 
estimates were less precise in multi-PFAS models. As we reported in our single-PFAS 
models, we found no meaningful associations between PFAS concentrations and 
maternal T4 or TSH. Associations in the multi-PFAS models between FT4I were 
attenuated and less precise, indicating possible confounding by the other PFASs. The 
association between PFOA and FT4I was no longer statistically significant. Variance 
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inflation factors (VIFs) for the PFASs ranged from 1.17 (PFHxS) to 3.00 (PFOS), 
indicating possible collinearity with PFOS.  
 Results from neonatal single- and multi-PFAS models are displayed in Table 4.4. 
Prenatal PFOA was significantly inversely associated with T4 levels in all neonates [-0.69 
µg/dL (-1.35, -0.03)] and among males only [-1.18 µg/dL (-2.30, -0.07)]. The magnitudes 
of these associations were somewhat stronger in multi-PFAS models compared to results 
of single-PFAS models, indicating potential confounding by the other PFASs. Other 
effect estimates were largely similar between multi-PFAS models and single-PFAS 
models, with smaller suggestive inverse associations between PFHxS and T4 in all 
neonate and in male only models. In multi-PFAS models, the association between PFOS 
and T4 was positive but imprecise, whereas in single-PFAS analyses the associations 
were all negative and imprecise. VIFs for PFOS in multi-PFAS models ranged from 2.58 
to 3.81, again indicating possible collinearity issues. 
 
WQS regression 
Maternal analysis 
 Table 4.5 summarizes the results of the WQS regression analysis of associations 
between maternal plasma PFAS concentrations and thyroid hormone levels. The results 
include the beta estimate and corresponding 95% CI and p-value for the WQS index 
(WQSPFAS) and the corresponding weighted mean of the estimated weights across the 
1,000 bootstrap samples for each individual PFAS. The beta estimates for the WQS index 
for maternal T4 and TSH were not significant, indicating that there was not a significant 
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association between the WQS index of PFAS levels and maternal T4 or TSH levels. The 
beta estimate for association between the WQS index and FT4I was significant, indicating 
that there was is a significant inverse association between maternal FT4I levels and the 
WQS index of PFAS levels. For every one-unit increase in PFAS WQS index, mean FT4I 
levels decreased by 3% (-5.16, -1.00). The weighted mean of the empirical weights for 
each PFAS, representing their relative contributions to the combined association with 
FT4I, were: MeFOSAA (29%) > PFOA (28%) > PFHxS (25%) > EtFOSAA (17%); 
PFOS and PFNA did not meaningfully contribute to the overall association.  
 
Neonatal analysis 
 Table 4.6 summarizes the results of the WQS regression analysis of associations 
between prenatal plasma PFAS concentrations and neonatal T4 levels, in all neonates and 
stratified by sex. The beta estimate for the association between the WQS index and T4 in 
female neonates was not significant. In all neonate and male neonate models, the WQS 
index was significantly inversely associated with T4 levels. A one-unit increase in the 
WQS index was associated with a decrease of 0.51 µg/dL (-0.95, -0.07) in mean T4 levels 
in all neonates and a decrease of 1.04 µg/dL (-1.62, -0.46) in mean T4 levels in male 
neonates. In all neonates, the relative contributions of individual PFASs to the overall 
association with T4 based on their weights were: PFHxS (34%) > PFOA (24%) > PFOS 
(20%) > MeFOSAA (18%); PFNA and EtFOSAA did not contribute meaningfully to the 
overall association. In male neonates, the relative contributions of individual PFASs to 
the overall association with T4 levels based on their weights were: PFHxS (48%) > PFOS 
   
 
 95
(34%) > PFOA (10%) > MeFOSAA (6%); PFNA and EtFOSAA did not contribute to the 
overall association.  
 
Sensitivity analysis 
 We ran WQS regression constraining the direction of association between the 
PFASs and each thyroid hormone in the opposite direction compared to our primary 
analyses above to investigate whether PFASs had significant associations with the 
hormones in opposite directions. Beta estimates for WQS indexes of analyses with 
maternal T4 and FT4I constrained positive, maternal TSH constrained negative, and 
neonatal T4 constrained positive were not statistically significant (data not shown). 
 
DISCUSSION 
The aims of this study were to assess the combined effect of prenatal plasma 
concentrations of six PFASs on maternal and neonatal thyroid hormone levels and to 
identify the individual PFASs that contributed to these effects. We built upon our 
analyses in Chapter 3, which assessed associations between PFASs and thyroid hormones 
in models containing individual PFASs, and further assessed associations using models 
containing all six PFASs at once in this analysis. Because traditional statistical methods 
are often limited in their ability to assess combined effects of multiple exposures, 
especially moderately to highly correlated exposures, we used the novel statistical 
method, WQS regression, as our primary analysis and compared results from WQS 
regression with traditional regression models. 
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 In WQS regression, we found a significant inverse association between the PFAS 
WQS index and maternal FT4I. Based on their weights, MeFOSAA, PFOA, PFHxS, and 
EtFOSAA contributed to this association, but PFOS and PFNA did not. In contrast, in 
multi-PFAS linear regression models, we found no significant associations between 
PFAS concentrations and maternal FT4I, although there was a suggestive inverse 
association between PFOA and FT4I. In our single-PFAS analysis in Chapter 3, we 
reported a significant inverse linear association between PFOA and FT4I, and 
significantly lower FT4I in the highest quartiles of PFOA, PFHxS, and MeFOSAA,. 
Unlike WQS regression, neither single nor multi-PFOS models using traditional 
regression identified EtFOSAA as being associated with FT4I. In both traditional and 
WQS regression analyses, no associations were observed between PFAS concentrations 
and maternal T4 or TSH.  
 In the neonatal WQS regression, we found a significant inverse association 
between the PFAS WQS index and T4 levels in all subjects as well as in male infants 
only, but not in females. Based on their estimated weights, the group of individual PFASs 
that contributed to the inverse association between the PFAS WQS index and T4 levels 
was the same in models including all neonates and including male neonates only: PFHxS, 
PFOA, PFOS, and MeFOSAA. The order of PFOA and PFOS in terms of relative 
contribution differed between the two groups. In contrast, in multi-PFAS linear 
regression models PFOA was significantly inversely associated with T4 levels and 
PFHxS was suggestively inversely associated with T4 levels in all neonates and in males. 
MeFOSAA associations with FT4I were inverse, but were imprecise. In Chapter 3, we 
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reported significant associations between higher levels of PFHxS, PFOA, and PFOS and 
lower T4 in all and male quartile models and PFHxS and PFOA in male continuous 
models. In multi-PFAS models, when controlling for all other PFASs, the direction of 
effect of PFOS switched from negative to positive in male, and female neonatal models, 
potentially due to the high correlation with PFOA or confounding by the other PFASs.   
While we did not see associations between coexposures to PFASs and T4 or TSH 
in our analyses, reductions in maternal FT4I (fT4) alone have been consistently associated 
with impaired fetal growth and neurodevelopment (de Escobar 2001; de Escobar et al, 
2004; Henrichs et al. 2013). Effects of low neonatal T4 on subsequent growth and 
development are less well characterized, but altered neonatal thyroid function has been 
associated with reductions in IQ, attention, and neurocognitive tests (Lyall et al. 2016; 
Rose et al. 2006; Simic et al. 2009).  
While there is growing evidence from both the epidemiology and toxicology 
literature that exposure to PFASs alters thyroid function, the mechanism(s) of effect 
remains unclear. There are multiple proposed mechanisms based on the toxicology 
literature, which may differ across specific PFAS chemicals. Proposed mechanisms 
include reduced responsiveness to the hypothalamic-pituitary-thyroid axis, increased 
hepatic clearance of T4, increased conversion of T4 to T3 by type 1 deiodinase, and 
competitive binding to thyroid hormone binding proteins (Long et al. 2013; Weiss et al. 
2009; Yu et al. 2009).  
Most toxicology studies investigating effects of PFAS exposure on thyroid 
function have investigated effects of PFOS or PFOA, but less is known about the 
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toxicological effects of other PFAS chemicals. Studies looking at a range of PFAS 
chemicals have demonstrated varying levels of effect based on PFAS structure (Long et 
al. 2013; Ren et al. 2015; Ren et al. 2016; Weiss et al. 2009). For example, PFAS binding 
affinity to the thyroid hormone transport protein, transthyretin, varies based on PFAS 
chain length and functional group (Ren et al. 2016; Weiss et al. 2009). Similarly, Ren et 
al. (2015) demonstrated that there is a structure-dependent binding relationship between 
PFASs and the human thyroid receptor (TR), where longer-chain PFASs with acid end 
groups had the highest binding affinity to TR. Long et al. (2013) showed differences in 
effects on the thyroid hormone system using the T-screen assay, across seven PFASs. 
While these specific differences in action across PFASs may not directly explain why our 
results indicate only certain PFASs were responsible for the joint effects on maternal 
FT4I and neonatal T4 levels, they demonstrate the potential for different toxicities and 
mechanisms of action across different PFAS chemicals. Further toxicological studies are 
needed to understand both the underlying mechanisms of the thyroid disrupting effects of 
PFASs, the differences across PFAS chemicals, and the potential combined effects, both 
interactive and non-interactive, of exposure to multiple PFASs.  
 Results from previous studies of associations between serum or plasma 
concentrations of PFASs and maternal and neonatal thyroid hormone levels have been 
inconsistent, likely due to the extreme heterogeneity in study design, population 
demographics, analysis techniques, and PFAS distributions (Ballesteros et al. 2016). The 
most consistent findings have been a positive association between PFASs and TSH in 
both maternal and neonatal analyses, with some studies also reporting an inverse 
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association between PFASs and maternal and/or neonatal free or total T4 levels 
(Ballesteros et al. 2016; Berg et al. 2015; Berg et al. 2016; Wang et al. 2013; Wang et al. 
2014). The inverse association between PFASs and maternal FT4I was also reported (fT4) 
in single-PFAS models in a Taiwanese cohort (Wang et al. 2014) and in TPOAb positive 
women in a Canadian cohort (Webster et al. 2014). Inverse associations between PFAS 
concentrations and neonatal T4 levels have also been reported in single-PFAS models in 
previous studies (Kim et al. 2011; Wang et al. 2014).  
Few previous studies have examined the combined effects of coexposure to 
multiple PFASs at once, and those that have done so have primarily used traditional 
regression models containing multiple PFASs in a single model (Chan et al. 2011; Shah-
Kulkarni et al. 2016). Berg et al. (2016) used principle components analysis and 
hierarchical clustering methods to assess associations between multiple pollutants, 
including several PFASs, and maternal thyroid hormone levels, due to high correlations 
between chemicals. However, these methods group exposures based on correlations with 
each other rather than on associations with the outcome. Thus, individual exposures 
within a component or correlated group may vary in respect to association with the 
outcome, but there is no way to disentangle these relationships within the components.  
The major strength of the present study was the use of WQS regression, which 
allowed us to examine both the joint effects of exposure to multiple PFASs on maternal 
and neonatal thyroid hormone levels as well as to identify the individual PFASs that 
contributed most to these associations. Using WQS regression we identified multiple 
PFASs that contributed to the significant joint effects of PFAS exposure on both maternal 
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FT4I and neonatal T4 levels, which were not identified using traditional linear regression 
analyses.  
Other strengths of the present study include the relatively large sample size, 
which allowed us to assess these complex relationships while controlling for multiple 
potential confounding factors, the prospective nature of our neonatal analysis, and the 
collection of maternal blood samples during early pregnancy. Unlike previous studies, we 
collected maternal blood samples during the first trimester of pregnancy, a period when 
offspring are particularly susceptible to the potential adverse neurodevelopmental effects 
of alterations in maternal thyroid hormone levels (de Escobar et al. 2004; Henrichs et al. 
2013). Physiological changes such as plasma volume expansion and increased glomerular 
filtration rate, which can affect both plasma PFAS concentrations and thyroid hormone 
levels, are less likely to be significant confounding factors during early pregnancy 
compared to later pregnancy. As previously reported in Chapter 3, controlling for these 
factors using plasma albumin and estimated GFR levels, in addition to gestational week 
at blood draw, did not affect our analyses.  
There are several potential limitations to the present study involving the 
underlying assumptions of WQS regression. WQS regression assumes a linear 
relationship between quartiles of exposures and the outcome of interest. In our analysis in 
Chapter 3, we assessed linearity of these relationships using generalized additive models 
(GAMs) and by visually inspecting associations across quartiles. The GAMs showed no 
significant departures from linearity in our models and while the results of quartile 
models do not show perfect monotonicity, they approximate linearity in most cases. WQS 
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also assumes that the exposures all have the same direction of effect on the outcome, and 
requires the user to constrain the direction of effect in a given direction for analysis. 
While we are not aware of toxicological evidence to support a difference in direction of 
effect across different PFASs, we ran all WQS regression analyses in both directions of 
effect to ensure that we were not missing significant associations between PFAS and 
thyroid hormone levels in the opposite direction of our primary analyses. Results these 
sensitivity analyses did not show any significant effects in the opposite direction of effect 
from our primary analyses. In addition, WQS assumes that there are no interactions 
between exposures. We are not aware of any toxicological data to indicate whether or not 
PFASs might interact with each other to have non-additive effects on thyroid hormone 
levels. This is an area where further research is necessary in both toxicologic and 
epidemiologic methods.  
In addition to the limitations of the WQS regression methods, there are several 
other general limitations of the present study. The Project Viva study population is of 
higher socioeconomic status and less racially diverse than the general population, limiting 
the generalizability of our study results. However, levels of PFASs in Project Viva were 
comparable to those in NHANES during the corresponding sampling time period (Sagiv 
et al. 2015). In both maternal and neonatal analyses we did not have a direct measure of 
iodine status, an important potential confounder, but we did have information on dietary 
intake of iodine rich foods. Our maternal analysis was cross-sectional, limiting our ability 
to determine temporality of exposure in relation to the outcome, but is potentially offset 
by the relatively long half-lives of PFASs in plasma, measured in years. In neonatal 
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analyses, we only had measures of T4 levels and were not able to explore associations 
with other thyroid hormone levels. While we did have a relatively large sample size, our 
neonatal sample was smaller and less robust to splitting the dataset during WQS 
regression. Therefore, we ran WQS regression in the full neonatal dataset without 
splitting it into training and test datasets, which can increase the Type I error rate. 
While we were able to assess potential confounding by numerous demographic 
and physiological factors as well as PFAS coexposures, we cannot rule out potential 
residual confounding from uncontrolled factors such as demographic factors or 
coexposures to additional thyroid disrupting chemicals. We also cannot rule out potential 
interactions between PFASs or other chemical coexposures. 
 
CONCLUSION 
 We examined the effect of coexposure to multiple PFAS chemicals on maternal 
and neonatal thyroid function using WQS regression, a novel statistical method used to 
assess associations between a group of correlated exposures and an outcome of interest. 
We found that joint exposure to PFASs, represented by the WQS index, was associated 
with lower FT4I in mothers, and that MeFOSAA, PFOA, PFHxS, and EtFOSAA 
contributed most to this association. In neonates, combined exposure to PFASs, 
represented by the WQS index, was associated with lower T4 levels in all neonates and in 
males, and that PFHxS, PFOA, and PFOS were the major contributors. This is the first 
epidemiologic study to use WQS regression to assess the mixture effects of multiple 
PFASs on thyroid hormone levels. Further studies are needed to confirm these results, to 
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explore potential interactions between PFASs, and to better understand the toxicological 
mechanism(s) behind these findings. 
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Table 4.1 Prenatal plasma PFAS and maternal and neonatal thyroid hormone distributions in the analytic 
study population 
 
Maternal Analysis (n=726) 
 
Neonatal Analysis (n=465) 
  
Median 
(25th – 75th percentile) 
Range 
 
Median 
(25th – 75th percentile) 
Range 
Prenatal plasma PFAS 
(ng/mL)      
 
PFOS 23.9 (17.6 – 32.6) 2.8 – 115 
 
23.3 (17.3 – 30.8) 4.6 – 115 
 PFOA 5.6 (3.9 – 7.7) 0.3 – 36.7  5.5 (3.9 – 7.5) 0.9 – 20.1 
 PFHxS 2.4 (1.6 – 3.7) <LOD – 43.2  2.3 (1.6 – 3.8) <LOD – 43.2 
 
PFNA 0.6 (0.5 – 0.8) <LOD – 6.0 
 
0.6 (0.5 – 0.9) <LOD – 6.0 
 
EtFOSAA 1.1 (0.7 – 1.7) <LOD – 33.6 
 
1.0 (0.7 – 1.7) <LOD – 33.6 
 
MeFOSAA 1.8 (1.2 – 2.9) 0.1 – 29.7 
 
1.8 (1.2 – 2.8) 0.1 – 29.7 
Thyroid hormones      
 
Total T4 (µg/dL) 9.9 (8.7 – 11.2) 3.9 – 24.4  
17.3 (14.8 – 20.2) 3.7 – 35.7 
 
Free T4 Index 2.1 (1.9 – 2.3) 1.3 – 6.0  
NA NA 
 
TSH (mIU/mL)a 1.2 (0.7 – 1.9) <0.01 – 19.3 
 
NA NA 
PFAS, per- and polyfluoroalkyl substances; PFOS, perfluorooctane sulfonate; PFOA, perfluorooctanoate; PFHxS, 
perfluorohexane sulfonate; PFNA, perfluorononanoate; EtFOSAA, 2-(N-ethyl-perfluorooctane sulfonamide) acetate; 
MeFOSAA, 2-(N-methyl-perfluorooctane sulfonamide) acetate; T4, thyroxine; TSH, thyroid stimulating hormone.  
The limits of detection (LOD) were 0.2 ng/mL for PFOS and 0.1 ng/mL for all other PFAS. 
an=718, 8 participants missing TSH values 
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Table 4.2 Spearman correlation coefficients among prenatal plasma PFAS concentrations (ng/mL) and maternal (n=726) and 
neonatal (n=465) thyroid hormones  
        Maternal  Neonatal 
 
PFOS PFOA PFHxS PFNA EtFOSAA MeFOSAA T4  FT4I TSHa  T4  
PFOS 1 0.74** 0.52** 0.63** 0.49** 0.39** 0.02 -0.01 -0.03  -0.05 
PFOA 
 
1 0.52** 0.55** 0.38** 0.36** 0.01 -0.07 0.01  -0.02 
PFHxS 
  
1 0.43** 0.19** 0.26** -0.05 -0.05 0.01  -0.06 
PFNA 
   
1 0.19** 0.24** -0.05 0.01 0.04  -0.01 
EtFOSAA 
    
1 0.41** -0.06 -0.04 -0.04  0.02 
MeFOSAA 
     
1 -0.003 -0.05 -0.08*  -0.05 
Maternal  
         
 
 
 
T4 (µg/dL)       
1 0.47** -0.24  0.02 
 
FT4I         
1 -0.34**  0.01 
 
TSH (mIU/mL) 
        
1  0.01 
Neonatal T4 (µg/dL)          
 1 
**p<0.0001, *p<0.05 
an=718, 8 participants missing TSH values 
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Table 4.3 Adjusteda change in maternal thyroid hormone level per IQR increase in plasma PFAS concentrations 
(n=726b) in (A) single- and (B) multi-PFAS models 
  Total T4 (µg/dL)   Free T4 Index   TSH ln(mIU/mL) 
  Beta (95% CI) VIF   
% change (95% 
CI) 
VIF   
% change (95% 
CI) 
VIF 
(A) Single-PFAS models 
        
PFOS 0.01 (-0.14, 0.16) 
  
-1.04 (-2.36, 0.29) 
  
0.84 (-7.32, 9.73) 
 
PFOA 0.09 (-0.09, 0.27) 
  
-1.75 (-3.30, -0.18) 
  
0.30 (-9.30, 10.9) 
 
PFHxS -0.05 (-0.14, 0.04) 
  
-0.58 (-1.36, 0.21) 
  
2.76 (-2.25, 8.03) 
 
PFNA -0.05 (-0.16, 0.05) 
  
-0.65 (-1.61, 0.33) 
  
-0.55 (-6.50, 5.77) 
 
EtFOSAA -0.01 (-0.09, 0.06) 
  
0.09 (-0.60, 0.78) 
  
-0.08 (-4.32, 4.36) 
 
MeFOSAA 0.03 -0.10, 0.15) 
  
-0.85 (-1.95, 0.27) 
  
1.05 (-5.84, 8.44) 
 
(B) Multi-PFAS model         
PFOS 0.05 (-0.20, 0.30) 3.00 
 
-0.37 (-2.58, 1.88) 3.00 
 
1.10 (-12.3, 16.5) 3.00 
PFOA 0.18 (-0.07, 0.43) 2.18 
 
-1.36 (-3.56, 0.88) 2.18 
 
-1.26 (-14.4, 13.9) 2.17 
PFHxS -0.07 (-0.16, 0.03) 1.17 
 
-0.34 (-1.17, 0.50) 1.17 
 
2.89 (-2.44, 8.51) 1.17 
PFNA -0.10 (-0.24, 0.03) 1.63 
 
-0.04 (-1.21, 1.14) 1.63 
 
-1.45 (-8.56, 6.21) 1.64 
EtFOSAA -0.05 (-0.15, 0.04) 1.56 
 
0.45 (-0.40, 1.30) 1.56 
 
-0.29 (-5.50, 5.20) 1.56 
MeFOSAA 0.01 (-0.12, 0.15) 1.23   -0.50 (-1.69, 0.70) 1.23   1.23 (-6.18, 9.23) 1.23 
aAll models adjusted for maternal age, race/ethnicity, smoking status, fish intake, parity, and gestational week at blood 
draw.  
bTSH n=718 
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Table 4.4 Adjusteda change in T4 (µg/dL) per IQR increase in prenatal plasma PFAS concentrations in all 
neonates and stratified by sex in (A) single- and (B) multi-PFAS models 
 
All Neonates (n=465)b 
 
Males (n=236)   Females (n=229) 
    Beta (95% CI) VIF   Beta (95% CI) VIF   Beta (95% CI) VIF 
(A) Single-PFAS models 
        
PFOS -0.09 (-0.44, 0.26) 
  
-0.38 (-0.91, 0.16) 
  
-0.14 (-0.66, 0.37) 
 
PFOA -0.45 (-0.92, 0.02) 
  
-1.02 (-1.81, -0.24) 
  
-0.32 (-0.97, 0.33) 
 
PFHxS -0.15 (-0.38, 0.09) 
  
-0.49 (-0.87, -0.11) 
  
0.09 (-0.23, 0.41) 
 
PFNA 0.09 (-0.25, 0.44) 
  
-0.30 (-0.89, 0.30) 
  
0.21 (-0.26, 0.68) 
 
EtFOSAA -0.08 (-0.27, 0.10) 
  
0.09 (-0.44, 0.61) 
  
-0.15 (-0.37, 0.06) 
 
  MeFOSAA -0.13 (-0.43, 0.17)     -0.07 (-0.45, 0.31)     -0.32 (-0.94, 0.30)   
(B) Multi-PFAS model 
        
PFOS 0.31 (-0.28, 0.90) 2.89 
 
0.21 (-0.59, 1.01) 2.58 
 
0.41 (-0.54, 1.35) 3.81 
PFOA -0.69 (-1.35, -0.03) 2.09 
 
-1.18 (-2.30, -0.07) 2.35 
 
-0.51 (-1.36, 0.34) 2.13 
PFHxS -0.14 (-0.38, 0.10) 1.16 
 
-0.31 (-0.70, 0.08) 1.21 
 
0.03 (-0.29, 0.35) 1.17 
PFNA 0.21 (-0.20, 0.62) 1.57 
 
0.20 (-0.46, 0.85) 1.51 
 
0.20 (-0.37, 0.77) 1.90 
EtFOSAA -0.08 (-0.31, 0.14) 1.60 
 
0.37 (-0.26, 1.00) 1.73 
 
-0.16 (-0.43, 0.10) 1.98 
  MeFOSAA -0.07 (-0.38, 0.24) 1.14   -0.05 (-0.44, 0.34) 1.23   -0.24 (-0.84, 0.36) 1.19 
aAll models adjusted for maternal age, race/ethnicity, smoking status, parity, gestational week at maternal blood draw, 
cesarean delivery, gestational age, and age at heel stick. 
bAdditionally adjusted for child sex 
Sex*PFAS interaction p-values: PFOS, 0.74; PFOA, 0.41; PFHxS, 0.08; EtFOSAA, 0.10; MeFOSAA 0.62 
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Table 4.5 Results of WQS regression of plasma PFAS concentrations and maternal thyroid hormone levels 
during early pregnancy (n=726a) 
  T4 (µg/dL)   Free T4 Index   TSH (mIU/mL) 
 Beta
b (95% CI) p-value  % change
c (95% CI) p-value  % change
c (95% CI) p-value 
WQSPFAS -0.02 (-0.26, 0.23) 0.907   -3.05 (-5.16, -1.00) 0.005   4.92 (-6.76, 17.35) 0.412 
PFAS 
Weighted mean 
weightsd 
SD   
Weighted mean 
weightsd 
SD   
Weighted mean 
weightsd 
SD 
PFOS 0.001 0.01 
 
0.003 0.03 
 
0.338 0.02 
PFOA 0.043 0.11 
 
0.283 0.24 
 
0.243 0.35 
PFHxS 0.217 0.22 
 
0.251 0.22 
 
0.036 0.11 
PFNA 0.15 0.15 
 
0.003 0.02 
 
0.05 0.33 
EtFOSAA 0.413 0.41 
 
0.168 0.19 
 
0.122 0.33 
MeFOSAA 0.176 0.18   0.291 0.23   0.211 0.08 
All models adjusted for maternal age, race/ethnicity, smoking status, fish intake, parity, and gestational week at blood 
draw 
aTSH n=718 
bEstimate represents the change in T4 levels per 1-unit increase in the WQSPFAS index 
cEstimate represents the % change in hormone level per 1-unit increase in the WQSPFAS index 
dWeighted average of 1,000 bootstrap weights 
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Table 4.6 Results of WQS regression of prenatal plasma PFAS concentrations and T4 levels (µg/dL) in all 
neonates and stratified by sex 
  All Neonates (n=465)a   Males (n=236)   Females (n=229) 
  Beta (95% CI) p-value   Beta (95% CI) p-value   Beta (95% CI) p-value 
WQSPFAS  -0.51 (-0.95, -0.07) 0.022  
-1.04 (-1.62, -0.46) 0.0005 
 
-0.22 (-0.33, 0.81) 0.467 
PFAS 
Weighted mean 
weightsb 
    
Weighted mean 
weightsb 
SD   
Weighted mean 
weightsb 
SD 
PFOS 0.206 0.24 
 
0.340 0.25 
 
0.030 0.11 
PFOA 0.242 0.25 
 
0.102 0.17 
 
0.280 0.30 
PFHxS 0.338 0.26 
 
0.483 0.22 
 
0.037 0.12 
PFNA 0.038 0.10 
 
0.013 0.05 
 
0.174 0.26 
EtFOSAA 0.0008 0.01 
 
0.0001 0.002 
 
0.021 0.10 
MeFOSAA 0.176 0.19   0.063 0.11   0.459 0.33 
All models adjusted for maternal age, race/ethnicity, smoking status, parity, gestational week at maternal blood draw, 
cesarean delivery, gestational age, and age at heel stick.  
aAdditionally adjusted for child sex.   
bWeighted average of 1,000 bootstrap weights       
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CHAPTER FIVE: CONCLUSION 
This research aimed to examine effects of exposure to TPHP and PFASs on 
human thyroid function. We performed analyses in two Boston, MA area cohorts, FlaRE, 
a longitudinal study in adult male and female office workers, and Project Viva, a 
longitudinal pre-birth cohort. In Chapter 2, we characterized exposure to TPHP in FlaRE 
study participants by measuring its urinary metabolite, DPHP, and assessed associations 
between DPHP concentrations and serum thyroid hormone levels. In Chapter 3, we 
evaluated associations of prenatal exposure to individual PFASs with prenatal maternal 
and neonatal thyroid hormone levels in Project Viva. Building upon Chapter 3, we 
examined mixtures effects of prenatal exposure to multiple PFASs on maternal and 
neonatal thyroid function using both traditional and novel statistical methods in Chapter 
4.  
 
Chapter 2: Associations between urinary diphenyl phosphate and thyroid function 
We assessed exposure to TPHP by quantifying urinary DPHP concentrations in 
adult and child participants of the FlaRE cohort. In contrast to previous studies over 
shorter time periods, we found high within-subject variability in adult urinary DPHP 
concentrations over the one-year study period. As seen in previous studies, women had 
higher DPHP concentrations compared to men, and DPHP concentrations were higher in 
samples collected in the afternoon and evening compared to those collected in the 
morning. These differences could be due to differences in exposure patterns or 
physiological differences in metabolism and excretion. Unlike previous studies in 
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younger children, DPHP concentrations in the small sample of FlaRE participants’ 
children were similar to those in adults.  
We assessed associations between urinary DPHP concentrations and serum 
thyroid hormone levels in repeated samples from adult participants. After controlling for 
potential confounding factors, high urinary DPHP concentrations were associated with 
lower total T4 levels. Sex modified the association between DPHP concentrations and 
total T4 levels; compared to the full population, in stratified analyses effect estimates 
were strengthened in women and were attenuated in men. We did not find associations 
between urinary DPHP concentrations and TSH, free T4, or total T3 levels. These findings 
suggest that TPHP exposure could result in increased circulating total T4 levels and that 
the effects of exposure may differ based on sex.  
 
Chapter 3: Exposure to PFASs during pregnancy and maternal and neonatal thyroid 
function 
We assessed prenatal exposure to PFASs during the first trimester of pregnancy 
by measuring maternal plasma PFAS concentrations; maternal thyroid function was 
assessed using TSH, total T4, FT4I, and TPOAb levels measured in the same plasma 
samples. We assessed neonatal thyroid function using total T4 levels measured in whole 
blood from post-birth heel sticks. Maternal thyroid hormone levels were not associated 
with neonatal T4 levels. Women with higher plasma concentrations of PFOA, PFHxS, 
and MeFOSAA had significantly lower FT4I compared to women with lower 
concentrations. TPOAb status modified the association between PFAS concentrations and 
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TSH levels: in TPOAb positive women, increases in PFOA, PFOS, and PFNA 
concentrations were associated with lower TSH levels, but associations in TPOAb 
negative women were null. We did not find meaningful associations between PFAS 
concentrations and total T4 levels.  
In neonates, higher prenatal plasma PFHxS, PFOA, and PFOS concentrations 
were associated with lower T4 levels in all neonates and male neonates, but associations 
in female neonates were null. Pregnancy-induced changes in physiological factors, such 
as plasma volume expansion, measured by plasma albumin levels, and increases in GFR, 
did not confound our results. In both maternal and neonatal analyses, individual 
associations between PFASs and thyroid hormone levels varied across PFASs, indicating 
that effects of PFAS exposure may vary by individual PFAS. Our findings support the 
hypothesis that prenatal exposure to PFASs may alter thyroid function in both mothers 
and their infants. Further studies are needed to assess how these effects may vary by 
neonatal sex or preexisting thyroid dysfunction, such as thyroid autoimmunity.   
 
Chapter 4: Application of weighted quantile sum regression to assess combined prenatal 
exposure to PFASs and maternal and neonatal thyroid function  
Building upon our analysis in Chapter 3, assessing associations of prenatal 
plasma concentrations of individual PFASs with maternal and neonatal thyroid function, 
we assessed associations of coexposure to multiple PFASs with maternal and neonatal 
thyroid function using both traditional and novel regression methods. In traditional linear 
regression models containing all six PFASs, effect estimates for associations of PFASs 
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and maternal FT4I were attenuated compared to those from single-PFAS models in 
Chapter 3. In multi-PFAS models, only PFOA was suggestively inversely associated 
with maternal FT4I levels. In neonates, results of multi-PFAS linear regression models 
also differed compared to results from the single-PFAS models in both magnitude of 
association and direction of associations for some PFASs, such as PFOS. Effect estimates 
for associations between PFOS and neonatal T4 levels were negative in single-PFAS 
models, but were positive in multi-PFAS models, potentially due to collinearity with 
PFOA or confounding by other PFASs. Prenatal PFOA concentrations remained 
significantly inversely associated with neonatal T4 levels and PFHxS was suggestively 
inversely associated with neonatal T4 in multi-PFAS models. These results indicate that 
coexposures to other PFASs may confound associations of individual PFASs with thyroid 
hormone levels, which should be addressed in future studies.  
In WQS regression analyses including all six PFASs, the PFAS WQS index was 
significantly inversely associated with maternal FT4I. Based on the estimated empirical 
weights, MeFOSAA, PFOA, PFHxS, and EtFOSAA contributed to this effect, but PFOS 
and PFNA did not. The PFAS WQS index was not associated with maternal total T4 or 
TSH levels, as expected from our traditional regression analyses. In neonates, the PFAS 
WQS index was significantly inversely associated with T4 levels in all neonates and 
males, but not females. Based on the estimated empirical weights for the PFASs, PFHxS, 
PFOS, PFOA, and MeFOSAA contributed to this effect, but EtFOSAA and PFNA did 
not. These results indicate that there may be a cumulative negative effect of coexposure 
to some but not all PFASs on maternal FT4I and neonatal T4 levels.  
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Results from traditional linear regression and WQS regression analyses differed. 
Traditional linear regression results identified potential confounding by coexposure to 
PFASs, but estimates may have been affected by the high correlation between PFOA and 
PFOS (rs = 0.74). In both maternal and neonatal analyses, WQS regression identified 
more PFASs as important contributors to the associations between multi-PFAS 
coexposure and thyroid hormone levels compared to linear regression analyses. Unlike 
WQS regression, the results of linear regression models did not support a cumulative 
effect from exposure to multiple PFASs on maternal FT4I; instead PFOA was highlighted 
as the only PFAS associated with lower FT4I. Further research is needed to understand 
how to interpret differences in results from these methods, especially WQS regression, 
and their application for assessing associations of multiple correlated exposures with 
health effects.  
 
Study Limitations 
Detailed study-specific limitations are discussed in Chapters 2–4. There were 
some common methodological limitations across studies, which are outlined below. First, 
both studies used biomarkers to assess individuals’ exposures, which may have been 
subject to measurement error, resulting in exposure misclassification. In FlaRE, we 
measured urinary DPHP as a biomarker of TPHP exposure. However, DPHP is not a 
unique metabolite of TPHP and may also represent exposure to other aryl-phosphate 
flame retardants (Ballesteros-Gomez et al. 2015). In addition, DPHP is not the only 
metabolite of TPHP (Van den Eede et al. 2013). Therefore, associations observed 
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between urinary DPHP concentrations and thyroid hormone levels may reflect effects of 
exposure to other parent compounds or cumulative exposures to multiple parent 
compounds, not just exposure to TPHP. Additionally, we measured DPHP in spot urine 
samples collected every six months. While previous studies have reported relatively high 
reliability in DPHP concentrations over short time periods (days to months), we found 
much more variability in individuals’ DPHP concentrations over our longer one-year 
study period. This may indicate that our spot urine samples may not have accurately 
represented an individual’s TPHP exposure over our study period, leading to potential 
nondifferential exposure misclassification, which may have made it more difficult to see 
associations between DPHP concentrations and thyroid hormone levels even if they do 
exist. However, DPHP concentrations from spot urine samples may adequately 
characterize an individual’s exposure over shorter time periods, which may be sufficient 
to assess changes in circulating thyroid hormone levels that can change over relatively 
short time periods (days).  
 In Project Viva, we measured plasma PFAS concentrations to characterize 
prenatal exposure to PFASs. However, as discussed in Chapter 3, plasma PFAS 
concentrations can be affected by pregnancy-induced changes in physiology including 
plasma volume expansion and increases in GFR (Loccisano et al. 2013). Because parallel 
changes in thyroid physiology can affect circulating thyroid hormone levels, these factors 
could not only lead to potential exposure misclassification, but could also cause potential 
confounding of the associations of plasma PFAS concentrations with circulating thyroid 
hormone levels (Zantour et al. 2013). While controlling for plasma albumin levels and 
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eGFR did not confound the associations we observed, having only a single (cross-
sectional) measure of both PFASs and thyroid hormone levels in mothers may have led to 
both exposure and outcome misclassification in our studies.  
 Another common limitation in these studies was the reliance on thyroid hormone 
levels as markers of thyroid function. In both studies we observed associations of 
exposures with some, but not all, of the measured thyroid hormone levels. In FlaRE, we 
saw associations between DPHP and total T4, but not TSH, free T4, or total T3. 
Understanding the potential mechanism behind these results is difficult without measures 
of additional markers of thyroid function (e.g. thyroid hormone binding proteins or 
deiodinase activity). In Project Viva, we found associations between PFASs and maternal 
FT4I, but not TSH or total T4 levels. Given the lack of T3 measurements or other markers 
of thyroid function (e.g. thyroid binding globulin, deiodinase activity, or liver 
detoxification enzymes), we are only able to speculate about potential mechanism behind 
the associations with only FT4I. Similarly, in neonates, we only had measures of total T4 
levels, and measures of TSH and free T4 and T3 would have provided more insight into 
impacts on the thyroid system as a whole.   
Generalizability of study findings is another limitation of all three studies. Both 
the FlaRE and Project Viva study populations were more highly educated, of higher 
socioeconomic status, and less racially diverse, compared to the general U.S. population. 
While this may increase the internal validity of the present studies by potentially reducing 
residual confounding, the results may not be generalizable to the entire U.S. population. 
However, in terms of exposure levels, urinary DPHP concentrations were comparable to 
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those seen in other studies across the U.S. (Hoffman et al. 2017) and PFAS 
concentrations in Project Viva were comparable to those seen in NHANES from the 
corresponding time period (Sagiv et al. 2015).  
 
Public health implications 
Chapter 2 represents the first study to examine associations of TPHP exposure 
with thyroid function in a mixed-sex cohort. Results from Chapter 2 indicate that 
exposure to TPHP may alter circulating levels of thyroid hormone, especially among 
women. As seen in Chapter 2, as well as in previous studies, women may also have 
higher exposures to TPHP compared to men. These findings together suggest that women 
may be at greater risk of altered thyroid function from exposure to TPHP compared to 
men. The magnitude of the association between high urinary DPHP concentrations and 
increased total T4 levels in women was relatively small and may not have significant 
clinical impacts for an individual; however, because exposure to TPHP is ubiquitous and 
may be increasing (Hoffman et al. 2017), thyroid disruption from exposure to TPHP 
could have significant public health impacts on the population level. Thyroid disorders 
are common in both men and women, but the prevalence of thyroid disorders is 
significantly higher in women compared to men (Vanderpump 2011). Small changes in 
circulating T4 levels due to exposure to TPHP could shift individuals with subclinical 
thyroid disease towards clinical thyroid disease or shift euthyroid individuals towards 
subclinical thyroid disease. Even subclinical thyroid disease has been associated with 
adverse cardiac endpoints, neuropsychiatric symptoms, reduced bone mineral density, 
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and adverse reproductive endpoints (Surks et al. 2004). However, the findings from 
Chapter 2 were based on a relatively small sample size, used spot urine samples, and are 
the first to assess associations between TPHP exposure and thyroid function in women, 
and should therefore be interpreted with caution. Further research is needed in larger 
mixed-sex populations to replicate these findings and to further understand the 
associations between TPHP exposure and thyroid function. 
 The findings of Chapter 3 add to an increasing body of evidence indicating that 
prenatal exposure to PFASs may alter both maternal and neonatal thyroid function. 
Specifically, exposure to PFASs during early pregnancy may decrease levels of maternal 
free T4 and neonatal T4. While the majority of both maternal and neonatal study subjects 
had hormone levels within normal ranges, even the relatively small changes in hormone 
levels associated with PFAS exposure could have significant impacts at both the 
individual and population level. Hypothyroxinemia during pregnancy has been associated 
with adverse neurodevelopment in offspring both at birth and in later childhood (Kooistra 
et al. 2006; Lyall et al. 2016; Rose et al. 2006; Simic et al. 2009). Chapter 3 is the first 
study to assess associations between exposure to PFASs and maternal thyroid function 
during the first trimester of pregnancy, which has been shown to be a more sensitive time 
period for neurodevelopment effects of maternal hypothyroxinemia (Kooistra et al. 
2006). PFASs may be associated with adverse neurodevelopment, although the 
mechanism for this effect is unknown (Mariussen 2012; Oulhote et al. 2016). The thyroid 
disrupting effects of exposure to PFASs during pregnancy may be a potential mediator 
for the associated neurodevelopmental effects of PFAS exposure. Further research is 
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needed to better understand the mechanisms behind the associations of PFAS exposure 
and maternal and neonatal thyroid dysfunction as well as the associated consequences of 
these effects for both mother and child.  
 Building upon results found in Chapter 3, findings from Chapter 4 indicate that 
there may be a significant cumulative effect of coexposure to multiple PFASs during 
early pregnancy and both maternal and neonatal thyroid hormone levels, and effects of 
exposure to PFASs may vary by chemical. Because individuals are exposed to mixtures 
of PFASs and other potential thyroid disrupting chemicals, not just a single chemical at 
once, it is necessary to consider cumulative effects from simultaneous exposure to 
multiple chemicals. Small effects of exposure to a single PFAS chemical on thyroid 
hormone levels in an individual may not appear clinically relevant, but cumulative effects 
of exposures to multiple PFASs and other thyroid disrupting chemicals may have much 
more significant impacts in an individual. Because many of these chemicals are 
ubiquitous, population level effects are potentially of significant concern. It is necessary 
to understand both the individual and cumulative effects of these chemicals, as results 
from Chapters 3 and 4 indicate that not all PFASs were associated with thyroid hormone 
levels. This suggests that the potencies and/or mechanisms of chemicals may differ even 
within a chemical class. Further research is needed to examine the effects of coexposures 
to PFASs and other environmental chemicals on thyroid function. 
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Directions for future research 
 Chapter 2 represents the second study to examine associations between TPHP 
exposure and human thyroid function, and the first to do so in a mixed-sex cohort. Future 
research is needed in larger multi-sex study populations to further examine the 
associations between TPHP exposure and thyroid function and the potential effect 
modification by sex. These studies should include more frequent urine sampling to better 
characterize an individual’s DPHP levels over the study period. Because DPHP is neither 
the unique nor sole metabolite of TPHP, future studies should also measure other TPHP 
urinary metabolites, such as its hydroxylated metabolites, to further understand the 
relationships between TPHP exposure, metabolism, and excretion, and to determine the 
appropriateness of DPHP alone as a biomarker of exposure TPHP. To better understand 
potential mechanisms behind associations of TPHP exposure and altered thyroid hormone 
levels, future studies should include more comprehensive measures of thyroid function, 
such as serum thyroid hormone binding protein levels, TPOAb levels, and deiodinase 
activity. While Chapter 2 controlled for coexposure to PBDEs, future studies should 
include other common coexposures that may be associated with thyroid disruption, such 
as other PFRs.  
 Building upon the results from Chapters 3 and 4, future research examining the 
effects of exposure to PFASs on maternal and neonatal thyroid hormone should include 
multiple prospective measures of thyroid hormone levels, as maternal levels vary 
throughout pregnancy and are affected by pregnancy-induced changes in physiology. 
Future research should use a more comprehensive assessment of markers of thyroid 
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function in both mothers and neonates, when possible, such as measures of all thyroid 
hormones (e.g. TSH and free and total T4 and T3), levels of serum thyroid hormone 
binding proteins, and deiodinase activity, to help better understand potential mechanisms 
of these effects. Accurate measurement of maternal iodine status is also necessary, to 
control for potential confounding affects of iodine insufficiency during pregnancy, as 
iodine and PFASs may share common dietary sources, such as fish.  
 Future studies using novel statistical methods are needed to disentangle the 
individual and cumulative effects of coexposures to PFASs on thyroid function, and 
should also investigate potential interactions between PFAS chemicals. Future studies 
should also consider effects of coexposures to PFASs and other relevant coexposures, 
such as organochlorines, PBDEs, and other flame retardants.  
 In addition to further understanding the effects of exposure to PFASs on maternal 
and neonatal thyroid function, future studies should examine potential downstream 
consequences of these associations, such as adverse pregnancy outcomes and 
neurodevelopmental deficits in offspring. Longitudinal pre-birth cohorts are the ideal 
venue for this research, as exposures and thyroid hormones can be measured during 
pregnancy and at birth and subsequent outcomes of interest can be assessed in the 
participants over time. Additional work in Project Viva will explore whether the thyroid 
hormone disrupting effects of PFASs seen in Chapters 3 and 4 may mediate 
neurodevelopmental effects of PFAS exposure. 
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